- Conditions: HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Metastatic Pancreas Cancer
Interventions: Drug: 5FU, leucovorin, oxaliplatin; Drug: Gemcitabine
Sponsors: Alberta Health Services; Alberta Health Services
Not yet recruiting - verified April 2012 - Conditions: Lung Cancer; Breathlessness
Intervention: Behavioral: Self-management Intervention
Sponsors: University Health Network, Toronto; University Health Network, Toronto; National Lung Cancer Partnership; Oncology Nursing Society Foundation; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Radiation: focal salvage HDR prostate brachytherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Not yet recruiting - verified April 2012 - Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Conditions: Uterine Neoplasms; Sentinel Lymph Node Biopsy
Intervention: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Hamilton Health Sciences Corporation; Hamilton Health Sciences Corporation; Juravinski Cancer Centre Foundation
Not yet recruiting - verified March 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Ganetespib
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified May 2012 - Conditions: Breast Neoplasms; Lymphedema
Interventions: Behavioral: Night-time compression system garment; Behavioral: Day-time compression sleeve
Sponsors: University of Alberta; University of Alberta; Alberta Health Services; Canadian Breast Cancer Foundation
Recruiting - verified April 2012 - A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate CancerCondition: Prostatic Neoplasms
Intervention: Drug: Degarelix (Firmagon)
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Active, not recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Other: Oncology Interactive Navigator; Other: Routine Care
Sponsors: McGill University; McGill University
Recruiting - verified May 2012 - Condition: Metastasis to Brain of Primary Cancer
Intervention: Radiation: Whole brain external beam radiation with simultaneous in-field boost
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; Ontario Institute for Cancer Research
Recruiting - verified February 2012 - Condition: Head and Neck Cancer
Intervention: Radiation: Dynamic Contrast Enhanced CT scan
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; London Regional Cancer Program, Canada
Not yet recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Procedure: Fine needle aspiration assessing tumour TNFa levels
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Not yet recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Behavioral: Nutrition and Exercise Group; Behavioral: Yoga and Stretching Group
Sponsors: University of Waterloo; University of Waterloo; Grand River Regional Cancer Centre
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Radiation: BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; Canadian Institutes of Health Research (CIHR)
Enrolling by invitation - verified March 2012 - Conditions: Colorectal Neoplasm; Biliary Tract Neoplasm; Liver Neoplasm
Interventions: Dietary Supplement: Whey protein and dietary supplements; Other: prehab exercise
Sponsors: McGill University Health Center; McGill University Health Center
Recruiting - verified February 2012 - Conditions: Renal Impairment; Kidney Diseases; Urologic Diseases; Cancer; Hypothermia; Kidney Cancer
Intervention: Procedure: Renal hypothermia
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Institutes of Health Research (CIHR)
Not yet recruiting - verified March 2012 - Condition: Cancer
Intervention: Drug: GSK2110183
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Mucinous Cystic Tumor With Moderate Dysplasia; Mucinous Cystadenoma of Pancreas; Mucinous Cystadenocarcinoma of Pancreas; Benign Neoplasm of Pancreas
Intervention: Drug: Ethanol and Paclitaxel Injection
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; University of Western Ontario, Canada
Not yet recruiting - verified February 2012 - Condition: Rectal Cancer
Intervention: Device: MRI,PET-CT and CT-Perfusion studies
Sponsors: London Health Sciences Centre; London Health Sciences Centre
Not yet recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: trastuzumab emtansine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Malignant Tumor of Extrahepatic Bile Duct
Interventions: Device: WInged perimeter biliary stent insertion (Viaduct); Device: traditional polyethylene stent insertion (Cotton Huibregtse)
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified January 2012 - Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Pancreatic Cancer
Interventions: Drug: LY2495655; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Suspended - verified May 2012 - Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012 - Conditions: Pancreatic Cancer; Hypoxia
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Cancer Society
Recruiting - verified March 2012 - Conditions: Breast Cancer; Non-small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012 - Conditions: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
Interventions: Drug: Everolimus; Drug: Everolimus Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Small Cell Lung Cancer
Interventions: Drug: Cabazitaxel XRP6258; Drug: Topotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Clear Cell, Metastatic Renal Cell Carcinoma
Intervention: Drug: Sunitinib
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Pfizer
Not yet recruiting - verified December 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012 - Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012 - Condition: Lung Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified December 2011 - Conditions: Colorectal Cancer; Colorectal Polyps
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified December 2011 - Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: Tivozanib; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012 - Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012 - Conditions: Infection; Bone Neoplasms
Intervention: Procedure: Prophylactic Cefazolin Antibiotic Regimen
Sponsors: McMaster University; Michelle Ghert
Not yet recruiting - verified April 2012 - Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012 - Conditions: Glioma; Metastatic Brain Cancer
Intervention: Device: ExAblate Transcranial System
Sponsors: InSightec; InSightec
Recruiting - verified March 2012 - Condition: Lung Neoplasms
Interventions: Drug: Afatinib; Drug: gefitinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Esophageal Cancer
Intervention:
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM)
Recruiting - verified November 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Breast Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified November 2011 - Condition: Neoplasms
Interventions: Drug: RO5503781; Drug: RO5503781
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiotherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Active, not recruiting - verified April 2012 - Condition: Cancer of the Endometrium
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Not yet recruiting - verified November 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012 - Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Drug: Sunitinib; Drug: Pazopanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012 - Condition: Endometrial Cancer
Interventions: Procedure: lymphadenectomy; Procedure: therapeutic conventional therapy; Procedure: Positron Emission Tomography/ Computed Tomography; Radiation: fludeoxyglucose F 18
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011 - Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Degarelix
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Not yet recruiting - verified November 2011 - Condition: Prostate Cancer
Interventions: Radiation: hypofractionation; Radiation: conventional
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital
Not yet recruiting - verified September 2011 - Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiation
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified January 2012 - Conditions: Esophageal Cancer; Precancerous Condition
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: afatinib; Drug: afatinib; Drug: Vinorelbine; Drug: Investigator's choice of treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Breast Cancer; Head and Neck Cancer
Interventions: Other: Aveeno cream and Flamazine cream; Other: Neoviderm cream; Other: Aveeno cream and Flamazine cream; Other: Neoviderm cream
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital; Avario Healthcare Inc.
Recruiting - verified April 2012 - Condition: Oligometastatic Tumors
Interventions: Radiation: Stereotactic ablative radiotherapy; Radiation: palliative radiotherapy
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; London Regional Cancer Program, Canada; VU University of Amsterdam
Recruiting - verified December 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Drug: Dutasteride
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Odette Cancer Centre Genito-Urinary Disease Site Group
Completed - verified February 2012 - FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate CancerCondition: Prostate Cancer
Interventions: Radiation: Stereotactic Body Radiation; Drug: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified September 2011 - Condition: Hematopoietic Neoplasm
Interventions: Drug: SAR302503; Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Thyroid Neoplasms
Interventions: Drug: CPERT; Drug: GPERT
Sponsors: Alberta Health Services; Alberta Health Services; Natural Resources, Canada; Edmonton PET Centre
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012 - Condition: Breast Neoplasms
Interventions: Other: Volume of Exercise; Moderate or High Volume; Other: Aerobic Exercise; Other: Aerobic Exercise
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified September 2011 - Condition: Breast Cancer
Intervention: Genetic: ONCOTYPEDX Test
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Recruiting - verified May 2012 - Conditions: Prostate Neoplasms; Prostate Cancer
Interventions: Drug: Abiraterone acetate and prednisone; low-fat diet; Drug: Abiraterone acetate and prednisone; high-fat diet
Sponsors: Janssen-Ortho Inc., Canada; Janssen-Ortho Inc., Canada
Recruiting - verified April 2012 - Condition: Prostatic Neoplasms
Interventions: Radiation: Image-guided radiotherapy; Radiation: Image-guided radiotherapy
Sponsors: CancerCare Manitoba; CancerCare Manitoba; Sunnybrook Health Sciences Centre
Recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Completed - verified September 2011 - Condition: Endometrial Neoplasms
Interventions: Drug: PF-04691502; Drug: PF-05212384; Drug: PF-04691502; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012 - Conditions: Gastrointestinal Neoplasms; Urogenital Neoplasms
Intervention: Procedure: Medical Acupuncture
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; BC Cancer Foundation
Active, not recruiting - verified August 2011 - Conditions: Breast Neoplasms; Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases
Interventions: Drug: Botulinum Toxin Type A; Drug: 0.9% Sodium Chloride
Sponsors: University of British Columbia; University of British Columbia; Vancouver Coastal Health; Providence Health & Services
Recruiting - verified January 2012 - Condition: Non Small Cell Lung Cancer
Intervention: Radiation: Stereotactic Body Radiation Therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified November 2011 - Condition: Hematopoietic Neoplasm
Intervention: Drug: SAR302503
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012 - Condition: Pancreas Cancer
Interventions: Drug: gemcitabine; Drug: 5-fluorouracil
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Conditions: Anus Neoplasms; Rectal Neoplasms; Urogenital Neoplasms
Interventions: Other: Aveeno cream; Other: Alkagin paste
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Dr. Te Vuong; Avario Healthcare
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Esophageal Cancer; Adenocarcinoma, Esophageal; Squamous Cell Carcinoma, Esophageal; Carcinoma, Gastroesophageal Junction
Interventions: Drug: carboplatin and paclitaxel; Other: Carboplatin paclitaxel plus concurrent radiotherapy
Sponsors: Capital District Health Authority, Canada; Gordon Buduhan; Capital Health, Canada
Recruiting - verified January 2012 - Condition: Advanced Rare Tumours
Interventions: Drug: Sunitinib; Drug: Temsirolimus
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Behavioral: Telephone Implementation Intention; Behavioral: Self-completed implementation intention
Sponsors: University of Alberta; University of Alberta
Active, not recruiting - verified August 2011 - Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011 - Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012 - Conditions: Bladder Cancer; Transitional Cell Carcinoma
Intervention:
Sponsors: University of British Columbia; University of British Columbia; Canadian Urologic Oncology Group
Not yet recruiting - verified July 2011 - Condition: Prostate Cancer
Intervention:
Sponsors: Abbott; Abbott; JSS Medical Research Inc.; CMX Research; CMX Research Inc
Recruiting - verified March 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Conditions: Cachexia; Non-Small Cell Lung Cancer
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Helsinn Therapeutics (U.S.), Inc; Helsinn Therapeutics (U.S.), Inc
Recruiting - verified May 2012 - Conditions: Hepatocellular Carinoma; Liver Cancer; HCC
Interventions: Biological: JX-594 recombinant vaccina GM-CSF; Other: Best Supportive Care
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics
Recruiting - verified November 2011 - Condition: Cancer-related Pain
Interventions: Drug: Lidocaine; Drug: Placebo (normal saline)
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; BC Cancer Foundation
Recruiting - verified March 2012 - Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012 - Condition: Neoplasms
Intervention: Drug: RO5458640
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Behavioral: Health counselling by nurse navigator; Behavioral: Usual primary care counselling
Sponsors: Cancer Care Ontario; Cancer Care Ontario; Canadian Institutes of Health Research (CIHR)
Recruiting - verified January 2012 - Conditions: Cervical Cancer; HPV Type 16/18 Infections
Intervention: Biological: GSK Biologicals' HPV vaccine 580299
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified March 2012 - Condition: Colorectal Cancer
Intervention: Drug: Pentamidine (OCZ103-OS), mFOLFOX6 or FOLFIRI
Sponsors: Oncozyme Pharma Inc.; Oncozyme Pharma Inc.
Recruiting - verified October 2011 - Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012 - Conditions: Neoplasms; Neoplasm Metastasis; Pancreatic Cancer
Interventions: Drug: LY2157299; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: CMX Research; CMX Research; Ferring Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Malignant Dysphagia; Esophageal Cancer
Interventions: Radiation: Brachytherapy; Procedure: Stent insertion
Sponsors: McGill University Health Center; McGill University Health Center
Not yet recruiting - verified June 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012 - Conditions: Cancer; Metastatic Malignant Neoplasm to Femur; Risk of Fracture
Interventions: Procedure: Surgery Alone; Other: Combined Surgery and Radiation therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: MK-1775; Drug: Placebo; Drug: paclitaxel; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Device: MRI assisted TRUS guided biopsy
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; OICR; Eigen
Recruiting - verified March 2012 - Conditions: Colorectal Cancer; Colorectal Cancer Stage III
Interventions: Behavioral: multimodal prehabilitation; Behavioral: multimodal prehabilitation
Sponsors: McGill University Health Center; McGill University Health Center; Society of American Gastrointestinal and Endoscopic Surgeons
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Renal Cell Carcinoma
Interventions: Biological: BMS-936558; Biological: BMS-936558; Biological: BMS-936558
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012 - Conditions: Non-small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Docetaxel; Drug: Combination of ganetespib and docetaxel
Sponsors: Synta Pharmaceuticals Corp.; Synta Pharmaceuticals Corp.
Recruiting - verified November 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Radiation: EBR plus HDRIB; Radiation: EBR
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Cancer Society
Recruiting - verified March 2012 - Condition: Head and Neck Neoplasms
Interventions: Drug: Placebo; Drug: Afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Advanced Solid Tumors
Intervention: Drug: MEK162 + RAF265
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Advanced Cancer
Interventions: Drug: PF-04691502; Drug: PD-0325901; Drug: PF-04691502; Drug: irinotecan; Drug: PF-05212384; Drug: irinotecan
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Procedure: acupressure therapy; Procedure: sham intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Small Cell Lung Cancer
Intervention: Radiation: Adaptive Radiation
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Drug: PX-866
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Oncothyreon Canada Inc.
Recruiting - verified March 2012 - Conditions: Carcinoma, Non-Small-Cell Lung; Cancer of the Gastrointestinal Tract
Interventions: Behavioral: Standard Exercise; Behavioral: Qigong Exercise
Sponsors: McGill University; McGill University; Jewish General Hospital
Active, not recruiting - verified February 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Other: Best Supportive Care; Drug: Panitumumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: MLN9708 plus Melphalan and Prednisone; Drug: MLN9708 plus Melphalan and Prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Procedure: Physician Receives QoL results; Procedure: Physician Does not receive the results
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Mount Sinai Hospital, Canada
Completed - verified December 2011 - Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Solid Tumor
Intervention: Drug: BEZ235 + MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Intervention: Drug: pomalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012 - Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: pomalidomide; Drug: dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Intervention:
Sponsors: Allegro Diagnostics, Corp.; Allegro Diagnostics, Corp.; Beth Israel Deaconess Medical Center; Columbia University; Vanderbilt University; University of British Columbia; University of Pennsylvania; New York University; Temple University; Indiana University; University of Alabama at Birmingham; University of Virginia; University of Missouri-Columbia; Louisiana State University Health Sciences Center in New Orleans; University of Dublin, Trinity College; Georgia Institute for Clinical Research, LLC
Active, not recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Breast Cancer Research Foundation
Recruiting - verified July 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Conditions: Locally Advanced or Metastatic Medullary Thyroid Cancer; Medullary Thyroid Cancer
Intervention: Behavioral: Patient outreach
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified November 2011 - Conditions: Pancreatic Cancer; Unresectable Pancreatic Cancer
Intervention: Radiation: stereotactic body radiotherapy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified December 2011 - Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: VGX 3100; Biological: Placebo
Sponsors: Inovio Pharmaceuticals; Inovio Pharmaceuticals
Recruiting - verified May 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Other: DE-CEDM and CE-BMRI
Sponsors: GE Healthcare; GE Healthcare
Recruiting - verified January 2012 - Condition: Renal Cell Carcinoma
Intervention: Drug: Tivozanib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011 - Condition: Lung Cancer
Intervention: Other: Multi-faceted intervention to improve continuity of care
Sponsors: Laval University; Laval University; Canadian Cancer Society
Recruiting - verified January 2012 - Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012 - Condition: Breast Cancer
Intervention: Behavioral: Exercise
Sponsors: University of British Columbia; University of British Columbia; Canadian Breast Cancer Foundation
Recruiting - verified February 2012 - Condition: Neoplasms
Interventions: Drug: Regorafenib (BAY73-4506) + warfarin + omeprazole + midazolam; Drug: Regorafenib (BAY73-4506) + rosiglitazone
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012 - Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012 - Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCondition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Operable T2-3N+M0 Rectal Cancer (Stage III)
Interventions: Drug: FOLFOX; Radiation: high dose rate endorectal brachytherapy
Sponsors: Sir Mortimer B. Davis - Jewish General Hospital; Sir Mortimer B. Davis - Jewish General Hospital; Sanofi-Aventis
Recruiting - verified January 2011 - Condition: Metastatic Breast Cancer
Interventions: Biological: CP-675,206; Radiation: External local radiation therapy
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Terminated - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Head and Neck Cancer
Interventions: Drug: capecitabine; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Regorafenib (BAY 73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified May 2012 - Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral CavityConditions: Squamous Cell Carcinoma (SCC) of the Oral Cavity; Squamous Cell Carcinoma of the Soft Palate
Interventions: Biological: LI plus CIZ; Other: Standard of Care (SOC); Biological: LI + SOC
Sponsors: CEL-SCI Corporation; CEL-SCI Corporation; Teva Pharmaceutical Industries; Orient Europharma Co., Ltd.
Recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: cediranib maleate; Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012 - Conditions: Colorectal Cancer; Liver Metastases
Intervention: Drug: Panitumumab, Oxaliplatin, 5-FU
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified May 2012 - Condition: Prostate Cancer Metastatic
Intervention: Drug: CABAZITAXEL
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Locally Recurrent or Metastatic Breast Cancer
Interventions: Drug: Imetelstat sodium; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: Geron Corporation; Geron Corporation
Active, not recruiting - verified March 2012 - Condition: Glioblastoma
Intervention: Drug: PX-866
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Oncothyreon Inc.
Recruiting - verified December 2011 - Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011 - Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Melanoma; Metastatic Melanoma to the Brain
Intervention: Drug: GSK2118436
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011 - Condition: Endometrial Cancer
Intervention: Drug: BN83495
Sponsors: Ipsen; Ipsen
Terminated - verified July 2011 - Condition: Bone Metastases
Interventions: Drug: Dexamethasone; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified March 2012 - Condition: Non Squamous, Non-small-cell Lung Cancer
Interventions: Drug: Tivantinib (ARQ 197) plus erlotinib; Drug: ARQ 197 placebo plus erlotinib
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Daiichi Sankyo Development Limited; ArQule
Active, not recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Zoladex
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Terminated - verified May 2012 - Condition: Pancreatic Cancer
Intervention: Drug: Pimonidazole hydrochloride
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified October 2011 - Condition: Melanoma
Interventions: Drug: GSK1120212; Drug: Chemotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Neoplasms Malignant
Interventions: Drug: dalotuzumab + MK-2206; Drug: dalotuzumab + MK-0752; Drug: Dalotuzumab + MK-8669 (ridaforolimus)
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus; Drug: cyclophosphamide; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: temozolomide; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Suspended - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012 - Condition: Locally Advanced Breast Cancer (LABC)
Intervention: Procedure: FLT PET and BOLD MRI scan
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG)
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Cixutumumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified April 2012 - Condition: Cancer
Interventions: Drug: GSK2118436; Drug: Dacarbazine (DTIC)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011 - Conditions: Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Device: MRS
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Localized Low-Risk Prostate Cancer
Intervention: Device: MRgFUS Treatment
Sponsors: InSightec; InSightec
Recruiting - verified February 2012 - Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Non Small Cell Lung Cancer; NSCLC
Interventions: Drug: OSI-906; Drug: Erlotinib; Drug: Placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Other: art therapy
Sponsors: McGill University Health Center; McGill University Health Center; The Cedars Cancer Institute
Recruiting - verified August 2011 - Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Available - verified April 2012 - Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: cediranib maleate; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified October 2010 - Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012 - Conditions: Volumetric Tumor Response and Lack of Tumor Progression; Quality of Life of Patients on Nilotinib Versus Not
Intervention: Drug: Nilotinib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Novartis
Recruiting - verified June 2011 - Condition: Non Small Cell Lung Cancer
Intervention: Procedure: Transthoracic Ultrasound
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified November 2011 - Conditions: Endometrial Cancer; Kidney Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: temsirolimus; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012 - Condition: Cancer
Interventions: Drug: GSK1120212; Drug: Gemcitabine; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Tamoxifen Citrate; Drug: Placebo
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI); St. Jude Children's Research Hospital; University Health Network, Toronto; Emory University; University of Michigan
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012 - Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Biological: GSK580299 (Cervarix™)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Human Papillomavirus Infection; Cervical Neoplasia
Interventions: Procedure: Gynaecological follow-up; Biological: Cervarix™; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906; Drug: erlotinib; Drug: placebo
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified April 2012 - Conditions: Leukemia; Solid Tumours
Intervention: Drug: SB939
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified April 2012 - Condition: Colonic Neoplasia
Intervention:
Sponsors: University of British Columbia; University of British Columbia; Canadian Society of Intestinal Research
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Radiation: Iodine 125 standard loose brachytherapy seeds; Radiation: AnchorSeed Iodine 125 brachytherapy prostate implant
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; BrachySciences
Active, not recruiting - verified June 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Suspended - verified February 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified April 2012 - Condition: Neoplasms
Interventions: Drug: BIBW 2992 low dose; Drug: BIBW 2992 medium dose; Drug: BIBW 2992 high dose; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: pemetrexed; Drug: BIBW 2992 low dose 6 day; Drug: BIBW 2992 high dose 6 day; Drug: BIBW 2992 medium dose 6 day
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012 - Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011 - Conditions: Advanced Solid Tumours; Breast Cancer
Interventions: Drug: pantoprazole sodium for injection; Drug: doxorubicin hydrochloride injection
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) and Exemestane; Drug: Placebo and Exemestane
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Neoplasms, Colorectal; Colorectal Cancer; Colorectal Carcinoma
Intervention: Other: (supplement) Calcium and Magnesium
Sponsors: Alberta Health Services; Alberta Health Services
Not yet recruiting - verified April 2012 - Conditions: Minimal Residual Disease; Leukemia, Lymphoblastic, Acute; Leukemia, Myelogenous, Acute
Interventions: Drug: Clofarabine; Drug: Cytarabine; Drug: Methotrexate; Drug: Cytarabine
Sponsors: Therapeutic Advances in Childhood Leukemia Consortium; Therapeutic Advances in Childhood Leukemia Consortium; Genzyme
Recruiting - verified November 2011 - Condition: Melanoma
Interventions: Drug: rIL-21; Drug: Dacarbazine
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Conditions: Neoplasms; Breast Neoplasms; Breast Cancer
Interventions: Drug: AZD8931; Drug: anastrozole; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention: Drug: Vitamin D
Sponsors: University of British Columbia; University of British Columbia; Lotte and John Hecht Memorial Foundation
Recruiting - verified November 2011 - Condition: The Role of Multimedia on Retention and Comprehension of Key Concepts for Surgical Options in Newly Diagnosed Breast Cancer Patients.
Interventions: Other: This group of patients will be exposed to multimedia; Other: No Media
Sponsors: McGill University Health Center; McGill University Health Center
Enrolling by invitation - verified April 2012 - Condition: Multiple Myeloma
Intervention: Drug: AT9283
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Conditions: Osteoporosis; Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Canadian Breast Cancer Research Alliance
Active, not recruiting - verified June 2010 - Condition: Prostate Cancer
Intervention: Radiation: Hypofractionated radiotherapy
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Canadian Association of Radiation Oncology
Active, not recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: Foretinib; Drug: Lapatinib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified April 2012 - Conditions: Bone Metastases; Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; AstraZeneca
Active, not recruiting - verified January 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: imetelstat; Drug: Bevacizumab
Sponsors: Geron Corporation; Geron Corporation
Active, not recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Procedure: thoracic ultrasound; Procedure: pleural aspiration
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Fonds de la Recherche en Santé du Québec; Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Society of University Surgeons
Completed - verified June 2011 - Condition: Recurrent Breast Cancer
Intervention: Drug: Foretinib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Other: MRI examination
Sponsors: Radboud University; Radboud University; Siemens AG; Mount Vernon Hospital; Multi-Imagem and CDPI, Rio de Janeiro, Brasil; Norwegian University of Science and Technology; University of California, Los Angeles; University Hospital, Ghent; Johns Hopkins University; German Cancer Research Center; Medical University of Vienna; University Health Network, Toronto; University of Heidelberg
Recruiting - verified July 2011 - Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Venous Thromboembolism
Interventions: Drug: Warfarin; Drug: Innohep®
Sponsors: LEO Pharma; LEO Pharma
Recruiting - verified February 2012 - Condition: Rectal Cancer
Intervention: Radiation: Radiation
Sponsors: Alberta Health Services; Alberta Health Services; IGAR Image guided adaptive radiotherapy
Recruiting - verified April 2012 - Condition: Non-small-cell Lung Cancer
Intervention: Drug: AUY922
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Castration Resistant Prostate Cancer
Interventions: Drug: OGX-427 and Prednisone; Drug: Prednisone
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; OncoGenex Technologies, Inc.
Recruiting - verified December 2011 - Condition: Neoplasms Malignant
Intervention: Drug: Crizotinib
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Medulloblastoma,; Rhabdomyosarcoma,; Neuroblastoma,; Hepatoblastoma,; High Grade Glioma,; Astrocytoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Pancreatic Neoplasms
Interventions: Drug: Leucovorin; Drug: OXALIPLATIN; Drug: Capecitabine; Drug: 5-Fluorouracil
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012 - Condition: Oral Cavity Cancer
Intervention: Drug: PF-00299804/Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Pfizer
Recruiting - verified September 2011 - Conditions: Lung Neoplasms; Carcinoma; Cancer of the Lung; Non-Small-Cell Lung Carcinoma
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: Vinorelbine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Eli Lilly and Company
Active, not recruiting - verified April 2012 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: IPI-926 plus gemcitabine; Drug: Placebo plus gemcitabine
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Active, not recruiting - verified November 2011 - Condition: Breast Cancer
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
Sponsors: Bayer; Bayer
Completed - verified November 2011 - Condition: Advanced Non-clear Cell Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: Sunitinib
Sponsors: Duke University; Duke University; Novartis; Pfizer
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: IMC-1121B; Biological: IMC-18F1; Drug: mFOLFOX-6
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Regorafenib (BAY73-4506); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012 - Conditions: Ovarian Cancer; Fallopian Cancer; Peritoneal Cancer
Intervention: Drug: ENMD-2076
Sponsors: EntreMed; EntreMed
Active, not recruiting - verified August 2011 - Condition: Metastatic Sarcoma
Intervention: Drug: SB939
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified April 2012 - Condition: Kidney Cancer
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified September 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Conditions: Cervical Cancer; Precancerous Condition
Intervention: Device: Multispectral Digital Colposcope (MDC)
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; National Cancer Institute (NCI)
Not yet recruiting - verified July 2011 - Condition: Colorectal Neoplasms
Interventions: Drug: Glutamine; Drug: Calcium and Magnesium
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Active, not recruiting - verified April 2012 - Condition: Epithelial Ovarian Cancer
Intervention: Procedure: Seprafilm™
Sponsors: University of British Columbia; University of British Columbia; Genzyme
Recruiting - verified November 2011 - Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexamethasone; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2011 - Conditions: Breast Cancer; Chronic Pain
Interventions: Procedure: Thoracic Paravertebral Block (TPVB); Procedure: Local Anesthetic
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Canadian Breast Cancer Foundation
Recruiting - verified July 2011 - Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012 - Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: BMS-908662; Drug: BMS-908662; Drug: Cetuximab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified March 2011 - Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin; Drug: paclitaxel; Drug: Drug: carboplatin
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012 - Condition: Relapsed Multiple Myeloma
Interventions: Drug: Dexamethasone; Drug: Lenalidomide; Drug: Carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Active, not recruiting - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: HDAC inhibitor SB939
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified March 2012 - Condition: Ovarian Cancer
Interventions: Drug: ABT-888; Drug: pegylated liposomal doxorubicin; Drug: temozolomide
Sponsors: Abbott; Abbott
Active, not recruiting - verified May 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011 - Conditions: Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: Isotonic, 0.9% sodium chloride
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceuticals USA
Active, not recruiting - verified March 2012 - Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011 - Condition: Thyroid Cancer
Intervention: Other: Decision aid exposure
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Ontario Ministry of Health and Long Term Care; Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified July 2011 - Condition: Lung Cancer
Interventions: Drug: MET/VEGFR2 inhibitor Foretinib; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified March 2012 - Condition: Astrocytic Tumors
Intervention: Drug: XL184
Sponsors: Exelixis; Exelixis
Active, not recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Conditions: Breast Cancer; Colon Cancer; Ovarian Cancer; Endometrium Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Behavioral: Physical Activity Resource Kit; Behavioral: Standard Materials
Sponsors: Athabasca University; Athabasca University; University of Alberta; University of Calgary; Alberta Health Services
Recruiting - verified January 2010 - Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Pain; Chronic Disease; Breast Cancer
Interventions: Dietary Supplement: Isolated soy protein; Dietary Supplement: Isolated milk protein
Sponsors: McGill University Health Center; McGill University Health Center; National Cancer Institute (NCI); Louise & Alan Edwards Foundation; Alan Edwards Centre for Research on Pain
Suspended - verified January 2012 - Condition: NON-SMALL CELL LUNG CANCER
Interventions: Dietary Supplement: IMN1207; Dietary Supplement: Casein
Sponsors: Immunotec Inc.; Immunotec Inc.
Active, not recruiting - verified June 2011 - Condition: Gastro-Intestinal Cancer
Interventions: Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan; Drug: Brivanib; Drug: Brivanib; Drug: Brivanib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012 - Conditions: Oral Cancer; High-grade Precancer
Interventions: Procedure: Fluorescence visualization device; Procedure: Fluorescence visualization device
Sponsors: University of British Columbia; University of British Columbia; Terry Fox Research Institute; British Columbia Cancer Agency
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Other: Isosulfan Blue (Patent Blue Dye V); Other: Isosulfan Blue (Patent Blue Dye V)
Sponsors: University of British Columbia; University of British Columbia
Not yet recruiting - verified April 2012 - Condition: Esophageal Cancer
Interventions: Procedure: Endoscopic Ultrasound (EUS); Procedure: Endobronchial Ultrasound (EBUS)
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); C.E.T.O.C. - CHUM Endoscopic Tracheobronchial and Oesophageal Center; Marcel and Rolande Gosselin Chair in Thoracic Surgical Oncology; Fonds de la Recherche en Santé du Québec; Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Completed - verified November 2011 - Condition: Uveal Melanoma
Intervention: Drug: CP-675,206
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified September 2011 - Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Cervical Cancer
Interventions: Drug: temsirolimus; Genetic: promoter methylation analysis; Genetic: fluorescence in situ hybridization; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified October 2011 - Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: capecitabine [Xeloda]; Drug: capecitabine [Xeloda]; Drug: trastuzumab [Herceptin]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple MyelomaCondition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)
Interventions: Procedure: Cardiac MRI; Biological: Biomarker Testing
Sponsors: St. Michael's Hospital, Toronto; St. Michael's Hospital, Toronto; Hoffmann-La Roche
Recruiting - verified August 2011 - Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011 - Condition: Metastatic Castration-Resistant Prostate Cancer
Intervention: Drug: dextromethorphan hydrobromide or theophylline
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Active, not recruiting - verified August 2010 - Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: BIBF 1120; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Healthcare of Atlanta; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; Phoenix Children's Hospital; Alberta Children's Hospital; University of Colorado, Denver; Seattle Children's Hospital; Johns Hopkins University; Children's Mercy Hospital-Kansas City, MO; MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Procedure: Cervical Mediastinoscopy; Procedure: Endobronchial Ultrasound (EBUS); Procedure: Endoscopic Ultrasound (EUS)
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Fonds de la Recherche en Santé du Québec; Society of University Surgeons; Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012 - Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Drug: PF-00299804; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Malignant Melanoma
Interventions: Drug: Vemurafenib; Drug: Dacarbazine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified October 2011 - Conditions: Advanced Solid Tumors With FGFR1 Amplication,; Advanced Solid Tumors With FGFR2 Amplication,; Advanced Solid Tumors With FGFR3 Mutation
Intervention: Drug: BGJ398
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012 - Conditions: Hepatocellular Carcinoma Non-resectable; Hepatocellular Carcinoma Recurrent; Carcinoma; Hepatocellular; Liver Diseases; Neoplasms by Histologic Type
Interventions: Drug: ABT-869; Drug: Sorafenib
Sponsors: Abbott; Abbott
Active, not recruiting - verified March 2012 - Conditions: Fallopian Tube Cancer; Metastatic Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Grupo Español de Investigación en Cáncer de Ovario; Cancer Research UK; Southwestern Oncology Group (SWOG)
Recruiting - verified March 2012 - Condition: Cancer of the Prostate
Intervention:
Sponsors: CMX Research; CMX Research; Sanofi-Aventis
Active, not recruiting - verified May 2011 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: bortezomib; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2011 - Conditions: Hematologic Malignancy; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Myelodysplasia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Hodgkin's Disease
Intervention: Drug: Ciclopirox Olamine
Sponsors: University Health Network, Toronto; University Health Network, Toronto; The Leukemia and Lymphoma Society
Recruiting - verified April 2012 - Condition: Colorectal Cancer
Intervention: Other: Needle core biopsies of liver metastasis
Sponsors: Jewish General Hospital; Jewish General Hospital; Quebec Clinical Research Organization in Cancer; Fonds de la Recherche en Santé du Québec
Recruiting - verified September 2011 - Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified October 2011 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Biological: necitumumab; Drug: gemcitabine; Drug: cisplatin
Sponsors: ImClone LLC; ImClone LLC; Parexel; PPD; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific; ICON Clinical Research
Active, not recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: docetaxel; Drug: FEC: 5-Fluorouracil/epirubicin/cyclophosphamide; Drug: carboplatin; Drug: trastuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.
Active, not recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: pemetrexed; Drug: cisplatin; Biological: IMC-11F8
Sponsors: ImClone LLC; ImClone LLC; Quintiles; Parexel; PPD; Medidata Solutions; Laboratory Corporation of America; University of Colorado, Denver; Thermo Fisher Scientific
Active, not recruiting - verified April 2012 - Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: figitumumab; Drug: Cisplatin (Or Carboplatin); Drug: Etoposide; Drug: Cisplatin (Or Carboplatin); Drug: Etoposide
Sponsors: Pfizer; Pfizer
Terminated - verified May 2012 - Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsors: Pfizer; Pfizer
Terminated - verified May 2012 - Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention: Biological: Donor lymphocyte preparation depleted of host functional alloreactive T-cells
Sponsors: Kiadis Pharma; Kiadis Pharma
Suspended - verified April 2012 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Lung Neoplasms; Cachexia
Interventions: Other: Blood draws; Biological: Oral administration of stable isotope (deuterium); Procedure: Metabolic rate testing
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified April 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012 - Condition: Bladder Cancer
Intervention: Drug: OGX-427
Sponsors: Vancouver Coastal Health; Vancouver Coastal Health; NCIC Clinical Trials Group; Vancouver General Hospital Foundation
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: 5-fluorouracil; Drug: epirubicin; Drug: cyclophosphamide
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified December 2011 - Conditions: Pancreatic Neoplasm; Pituitary Neoplasm; Nelson Syndrome; Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011 - Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: Cisplatin; Drug: Pemetrexed
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012 - Condition: Cancer
Intervention: Drug: dalteparin
Sponsors: Eisai Inc.; Eisai Inc.
Active, not recruiting - verified April 2012 - Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Glioblastoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: temozolomide; Radiation: Radiation therapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Zoladex
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified March 2012 - Conditions: Prostate Cancer; Sexual Dysfunction
Interventions: Drug: tadalafil; Other: placebo
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: EZN-2208, Cetuximab and Irinotecan
Sponsors: Enzon Pharmaceuticals, Inc.; Enzon Pharmaceuticals, Inc.
Active, not recruiting - verified September 2011 - Conditions: Nausea and Vomiting; Pain; Sleep Disorders; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: methadone hydrochloride; Other: questionnaire administration; Procedure: management of therapy complications
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Terminated - verified July 2011 - Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Sirolimus (Rapamune); Drug: Cyclosporin (Neoral) or Tacrolimus (Prograf)
Sponsors: St. Joseph's Healthcare Hamilton; St. Joseph's Healthcare Hamilton
Withdrawn - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012 - Condition: Small Cell Lung Carcinoma
Interventions: Drug: BMS-833923; Drug: Carboplatin; Drug: Etoposide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012 - Conditions: Solid Tumors and Lymphoma; Cancer
Intervention: Drug: GSK2141795
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified June 2011 - Conditions: Breast Cancer; Advanced Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Radiation: Prophylactic Cranial Irradiation
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified August 2011 - Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Conditions: Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis
Interventions: Drug: BMS-754807; Drug: cetuximab (Erbitux®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast CancerConditions: Breast Cancer; Invasive Breast Cancer
Intervention: Procedure: Sentinel Lymph Node Biopsy
Sponsors: Centre hospitalier de l'Université de Montréal (CHUM); Centre hospitalier de l'Université de Montréal (CHUM); Fondation du cancer du sein du Québec
Recruiting - verified June 2011 - Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Esophageal Neoplasms
Interventions: Other: Preoperative treatment of chemotherapy and radiation; Other: Postoperative treatment of chemotherapy and radiation
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute
Recruiting - verified June 2011 - Conditions: Neoplasms; Breast Neoplasms; Breast Cancer
Interventions: Drug: AZD8931; Drug: Paclitaxel; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified February 2012 - Conditions: Carcinoma, Pancreatic Ductal; Pancreatic Cancer; Pancreatic Disease
Interventions: Biological: AGS-1C4D4; Biological: Gemcitabine
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Agensys, Inc.
Active, not recruiting - verified March 2012 - Conditions: Lung Neoplasm; Small Cell Carcinoma
Intervention: Radiation: Hypofractionated Chest Radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified September 2011 - Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Cervical Cancer; Squamous Cell Carcinoma; Adenosquamous Carcinoma; Adenocarcinoma
Interventions: Procedure: CT Abdomen and Pelvis scan + whole body PET-CT scan; Procedure: CT Abdomen and Pelvis scan
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Recruiting - verified June 2011 - Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention: Drug: Metformin
Sponsors: Mount Sinai Hospital, Canada; Mount Sinai Hospital, Canada; Princess Margaret Hospital, Canada
Completed - verified January 2012 - Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244; Drug: docetaxel; Drug: Placebo
Sponsors: AstraZeneca; AstraZeneca
Completed - verified March 2012 - Condition: Non-small Cell Lung Cancer
Intervention: Radiation: Stereotactic Radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Interventions: Drug: RAD001; Drug: sunitinib
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate plus prednisone/prednisolone; Drug: placebo plus prednisone/prednisolone
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Active, not recruiting - verified May 2010 - Condition: Epithelial Ovarian Cancer
Intervention: Drug: Intraperitoneal (IP) Cisplatin
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada
Terminated - verified October 2011 - Conditions: Neoplasms, Prostate; Prostate Cancer; Benign Prostatic Hyperplasia
Intervention: Other: observational
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified October 2011 - Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012 - Condition: Advanced Gastric Cancer
Interventions: Drug: Everolimus; Drug: everolimus placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Drug: Metformin
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Jewish General Hospital
Active, not recruiting - verified July 2009 - Condition: Advanced Solid Malignancies
Intervention: Drug: HSP990
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Conditions: Solid Tumors; Ovarian Cancer
Interventions: Drug: OSI-906; Drug: Paclitaxel
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Metastatic Non-Small Cell Lung Cancer
Intervention: Drug: nimotuzumab
Sponsors: YM BioSciences; YM BioSciences; CIMYM BioSciences
Terminated - verified June 2011 - Condition: Lung Cancer
Interventions: Biological: anti-IGF-1R recombinant monoclonal antibody MK-0646; Drug: cisplatin; Drug: etoposide; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Everolimus, Exemestane; Drug: Placebo, Exemestane
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified May 2012 - Condition: Colorectal Carcinoma
Interventions: Biological: IMC-1121B (ramucirumab); Drug: Oxaliplatin; Drug: Folinic acid; Drug: 5-FU; Drug: 5-FU
Sponsors: ImClone LLC; ImClone LLC
Completed - verified November 2011 - Conditions: Colorectal Cancer; Colon Cancer; Adenomatous Polyps
Interventions: Other: Fecal occult blood test; Procedure: Virtual colonoscopy; Procedure: Optical colonoscopy
Sponsors: McMaster University; Hamilton Health Sciences Corporation; McMaster University
Terminated - verified January 2012 - Condition: Malignant Melanoma
Interventions: Drug: ABI-007; Drug: Dacarbazine
Sponsors: Celgene Corporation; Celgene Corporation; University of Arizona
Active, not recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011 - Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Intervention: Procedure: CT- simulation scan
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified August 2011 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: Panitumumab
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Active, not recruiting - verified February 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1Condition: Prostate Cancer
Intervention: Biological: DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
Sponsors: McMaster University; Hamilton Health Sciences Corporation
Recruiting - verified December 2011 - Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First RelapseCondition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsors: Morphotek; Morphotek
Active, not recruiting - verified March 2012 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: doxorubicin + cyclophosphamide; Drug: paclitaxel + pazopanib; Procedure: surgery; Drug: pazopanib monotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting - verified April 2012 - Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Albumin-bound paclitaxel (ABI-007)/Gemcitabine; Drug: Gemcitabine
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified May 2012 - Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Active, not recruiting - verified August 2011 - Study of Antioxidants on Prostate Tumors in Men Undergoing Radical Prostatectomy for Prostate CancerConditions: Cancer of the Prostate; Prostate Cancer; Prostatic Neoplasms
Interventions: Dietary Supplement: Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E; Drug: Placebo
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011 - Condition: Multiple Myeloma
Interventions: Drug: CC-4047; Drug: Dexamethasone
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Condition: Liver Tumors
Intervention:
Sponsors: Foothills Medical Centre; Foothills Medical Centre; Vancouver General Hospital; London Health Sciences Centre; Centre Hospitalier de l'Université de Montréal
Recruiting - verified March 2012 - Condition: Liver Cancer
Interventions: Drug: Brivanib; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified March 2011 - Condition: Prostate Cancer
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Active, not recruiting - verified November 2011 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: pemetrexed; Drug: pemetrexed; Drug: BI 6727
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012 - Condition: Bone Metastases
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Suspended - verified June 2011 - Condition: Head and Neck Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified November 2011 - Conditions: Anxiety Disorder; Cognitive/Functional Effects; Colorectal Cancer; Depression; Fatigue; Psychosocial Effects of Cancer and Its Treatment; Sleep Disorders
Interventions: Behavioral: exercise intervention; Other: counseling intervention; Other: educational intervention; Other: laboratory biomarker analysis; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: fatigue assessment and management; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified May 2012 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: Irinotecan, Xeloda and Oxaliplatin (IXO) Regimen with Avastin (Bevacizumab)
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Hoffmann-La Roche; Pfizer; Sanofi-Aventis; Ottawa Regional Cancer Foundation
Active, not recruiting - verified July 2011 - Condition: Metastatic Breast Cancer
Interventions: Drug: Fulvestrant + ZACTIMA; Drug: Fulvestrant + Placebo
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); AstraZeneca
Active, not recruiting - verified October 2011 - Conditions: Neoplasms, Breast; Advanced or Metastatic ErbB2-overexpressing Breast Cancer
Intervention: Drug: Lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Conditions: Brain Cancer; Cancer; Solid Tumor; Lymphoma
Intervention: Biological: 18F-FLT
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012 - Condition: Colonic Neoplasms
Interventions: Behavioral: Exercise Training; Other: Usual Care
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Pancreatic Cancer
Intervention: Drug: Pentamidine
Sponsors: Oncozyme Pharma Inc.; Oncozyme Pharma Inc.
Completed - verified June 2011 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Pemetrexed; Drug: BIBF1120; Drug: Folic Acid; Drug: BIBF1120 plus pemetrexed; Drug: Placebo plus pemetrexed; Drug: Folic Acid
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Intervention: Drug: pentamidine
Sponsors: Oncozyme Pharma Inc.; Oncozyme Pharma Inc.
Completed - verified June 2011 - Conditions: Skin Cancer; Melanoma; Metastatic Melanoma
Interventions: Drug: temozolomide; Drug: ABT-888; Drug: Placebo
Sponsors: Abbott; Abbott
Active, not recruiting - verified March 2012 - Condition: Prostate Neoplasm
Intervention: Procedure: Focal Phothtermal Ablation
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Completed - verified December 2008 - Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299, GSK Biological's HPV vaccine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cediranib maleate; Drug: paclitaxel; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified March 2012 - Condition: Advanced Cancer
Interventions: Drug: Capecitabine; Drug: Doxorubicin; Drug: Ixabepilone; Drug: Docetaxel; Drug: Paclitaxel; Drug: Brivanib alaninate
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Conditions: Melanoma; Resected Stage III Melanoma With Macroscopic Involvement
Interventions: Drug: GSK 2132231A; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012 - Condition: Ovarian Neoplasms
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified April 2012 - Conditions: Advanced Solid Tumors; Metastatic Solid Tumors
Interventions: Drug: BMS-754807; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012 - Conditions: Solid Tumors; Neoplasms, Breast; Cancer
Interventions: Drug: Lapatinib in combination with an anti-cancer agent; Drug: Lapatinib; Drug: Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified February 2012 - Conditions: Colon Cancer; Colorectal Cancer; Rectal Cancer; Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Bevacizumab; Drug: mFOLFOX6
Sponsors: Amgen; Amgen
Active, not recruiting - verified January 2012 - Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: trastuzumab (Herceptin®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2010 - Condition: Locally Advanced Breast Cancer
Intervention:
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Juravinski Cancer Centre Foundation
Completed - verified October 2011 - Conditions: Lung Cancer; Precancerous Condition
Interventions: Dietary Supplement: inositol; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2009 - Condition: Advanced Breast Cancer
Interventions: Drug: Bosutinib; Drug: Exemestane
Sponsors: Pfizer; Pfizer
Terminated - verified March 2012 - Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib; Drug: Capecitabine
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: R1507; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Terminated - verified August 2011 - Condition: Recurrent Glioblastoma
Interventions: Drug: Cediranib; Drug: Cediranib; Drug: Lomustine Chemotherapy
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified June 2011 - Condition: Metastatic Colorectal Cancer
Intervention: Drug: sorafenib + FOLFIRI
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute; Bayer
Active, not recruiting - verified October 2011 - Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: USHIFU, LLC; USHIFU, LLC
Recruiting - verified April 2012 - Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Cancer
Intervention: Drug: P1446A-05
Sponsors: Piramal Healthcare Limited; Piramal Healthcare Limited
Active, not recruiting - verified June 2011 - Condition: Endometrial Cancer
Interventions: Drug: ridaforolimus; Genetic: gene expression analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Head and Neck Neoplasms
Intervention: Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Conditions: Lung Neoplasm; Cell Hypoxia
Interventions: Other: 18F-FAZA; Other: 18F-Fluorodeoxyglucose (18F-FDG)
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Conditions: Anaplastic Astrocytoma; Glioblastoma
Interventions: Drug: trabedersen; Drug: temozolomide or carmustine for infusion or lomustine; Device: Drug delivery system for administration of AP 12009; Procedure: Placement of Drug Delivery System
Sponsors: Antisense Pharma; Antisense Pharma
Terminated - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; Southwestern Oncology Group (SWOG); Cancer and Leukemia Group B
Active, not recruiting - verified May 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Conditions: Lung Cancer; Tobacco Use Disorder
Interventions: Other: laboratory biomarker analysis; Other: screening questionnaire administration; Procedure: bronchoscopic and lung imaging studies; Procedure: computed tomography; Procedure: endoscopic biopsy; Procedure: quality-of-life assessment
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Active, not recruiting - verified March 2012 - Condition: Ovarian Cancer
Interventions: Drug: AZD2281; Drug: matching placebo
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified October 2011 - Condition: Prostate Cancer
Intervention: Procedure: 3T MR Spectroscopy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012 - Conditions: Locally Advanced Breast Cancer; Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified September 2011 - Condition: Solid Tumors
Intervention: Drug: cediranib
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012 - Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Prostatic Neoplasms
Interventions: Drug: Placebo + Docetaxel/Prednisone; Drug: Dasatinib + Docetaxel/Prednisone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012 - Condition: Hematologic Cancer
Intervention: Biological: elotuzumab (HuLuc63)
Sponsors: Abbott; Abbott; Bristol-Myers Squibb
Active, not recruiting - verified December 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: BMS-690514; Drug: Erlotinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified February 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: ASA404; Drug: Placebo; Drug: docetaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012 - Condition: Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: zoledronic acid; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified August 2011 - Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsors: Morphotek; Morphotek
Terminated - verified April 2012 - Conditions: Advanced Cancer; Metastatic Cancer; Lymphoma; Solid Tumors; Advanced Malignancies
Intervention: Drug: CPI-613
Sponsors: Cornerstone Pharmaceuticals, Inc.; Cornerstone Pharmaceuticals, Inc.
Active, not recruiting - verified January 2012 - Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: pegylated liposomal doxorubicin (PLD); Drug: EC20; Drug: EC20
Sponsors: Endocyte; Endocyte
Active, not recruiting - verified March 2012 - Condition: Glioma
Interventions: Drug: BIBW 2992; Drug: TMZ; Drug: BIBW 2992 plus TMZ
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Completed - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Procedure: SPECT/CT guided LM/SL
Sponsors: Lawson Health Research Institute; Lawson Health Research Institute; London Regional Cancer Program, Canada; University of Western Ontario, Canada
Terminated - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma; Carcinoma, Renal Cell
Interventions: Drug: Pazopanib; Drug: Sunitinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Drug: Docetaxel
Sponsors: Centre hospitalier universitaire de Québec; Centre hospitalier universitaire de Québec
Terminated - verified February 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Talactoferrin; Drug: Placebo
Sponsors: Agennix; Agennix
Active, not recruiting - verified August 2011 - Conditions: Advanced Colorectal Cancer; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum
Interventions: Drug: ABT-869; Drug: bevacizumab; Drug: oxaliplatin; Drug: folinic acid; Drug: fluorouracil; Drug: ABT-869
Sponsors: Abbott; Abbott; Genentech
Active, not recruiting - verified March 2012 - Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsors: Exelixis; Exelixis
Active, not recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Biological: ramucirumab (IMC-1121B); Drug: docetaxel; Other: placebo
Sponsors: ImClone LLC; ImClone LLC
Active, not recruiting - verified January 2012 - Conditions: Breast Cancer; Triple Negative Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: AZD2281; Drug: Paclitaxel
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012 - Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsors: Algeta ASA; Algeta ASA; Bayer
Active, not recruiting - verified September 2011 - Conditions: Testicular Cancer; Seminoma; Non-seminomatous
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified August 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Carboplatin-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsors: Pfizer; Pfizer
Terminated - verified January 2012 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer
Active, not recruiting - verified May 2012 - Conditions: Breast Cancer; Osteoporosis
Interventions: Other: biologic sample preservation procedure; Other: physiologic testing; Procedure: dual x-ray absorptometry
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified August 2011 - Condition: Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; St. Michael's Hospital, Toronto
Not yet recruiting - verified November 2008 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide and low-dose dexamethasone; Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles; Drug: Melphalan, Prednisone and Thalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified April 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Non-small Cell Lung Cancer; Breast Cancer; Head and Neck Cancer; Ovarian Cancer; Esophageal Cancer; Lymphoma
Intervention: Other: PET/CT scan
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Active, not recruiting - verified February 2012 - Condition: Extensive-stage Small Cell Lung Cancer
Interventions: Drug: Obatoclax; Drug: Obatoclax; Drug: Obatoclax; Drug: Carboplatin and etoposide
Sponsors: Gemin X; Gemin X; Cephalon
Completed - verified January 2012 - Condition: Transitional Cell Carcinoma
Intervention: Drug: Paclitaxel
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; Celgene Corporation
Recruiting - verified July 2011 - Conditions: or Gastro-esophageal Junction Adenocarcinoma That is Unresectable Due to Locally Advanced Metastatic, or Locally Recurrent Disease.; ErbB2 (HER2) Amplified Gastric; Neoplasms, Gastrointestinal Tract; Esophageal
Interventions: Drug: Lapatinib; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012 - Conditions: Ovarian Carcinoma; Breast Cancer
Intervention: Drug: AZD2281
Sponsors: AstraZeneca; AstraZeneca; British Columbia Cancer Agency
Active, not recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Intervention: Drug: cilengitide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified December 2010 - Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012 - Conditions: Cancer; GCT; Giant Cell Tumor of Bone; Benign GCT
Intervention: Drug: Denosumab
Sponsors: Amgen; Amgen
Recruiting - verified January 2012 - Condition: Renal Cell Carcinoma
Intervention: Biological: AGS-003+sunitinib
Sponsors: Argos Therapeutics; Argos Therapeutics
Active, not recruiting - verified January 2012 - Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsors: Pfizer; Pfizer
Terminated - verified January 2012 - Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: Semuloparin sodium (AVE5026); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified December 2011 - Condition: Breast Cancer
Intervention: Other: Cardio-vascular MRI
Sponsors: University of Calgary; University of Calgary
Terminated - verified October 2011 - Conditions: Breast Cancer; Estrogen Receptor-Positive Breast Cancer; Breast Cancer, Estrogen Receptor-Positive; ER+ Breast Cancer
Interventions: Drug: entinostat; Drug: exemestane
Sponsors: Syndax Pharmaceuticals; Syndax Pharmaceuticals
Active, not recruiting - verified April 2012 - Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Procedure: 3T MR Imaging; Procedure: C-Choline PET Scanning; Procedure: Gene Rearrangement
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Conditions: Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell
Interventions: Drug: CP 751,871 (Figitumumab); Drug: Erlotinib; Drug: Erlotinib
Sponsors: Pfizer; Pfizer
Terminated - verified April 2012 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: daunorubicin hydrochloride; Other: pharmacological study; Procedure: dual x-ray absorptometry
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Conditions: Kidney Cancer; Leukemia; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: dactinomycin; Drug: vincristine sulfate; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; GlaxoSmithKline
Active, not recruiting - verified May 2012 - Condition: Non Small Cell Lung Cancer
Interventions: Dietary Supplement: melatonin; Dietary Supplement: placebo
Sponsors: The Canadian College of Naturopathic Medicine; The Canadian College of Naturopathic Medicine; The Ottawa Hospital
Recruiting - verified February 2012 - Conditions: Hedgehog Pathway; Smoothened; Basal Cell Carcinoma (BCC); Basal Cell Nevoid Syndrome (BCNS)
Intervention: Drug: BMS-833923 (XL139)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified August 2011 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: ASA404; Drug: Placebo; Drug: carboplatin; Drug: Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Terminated - verified May 2012 - Condition: Prostate Cancer
Intervention: Drug: LBH589 (i.v. panobinostat)
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012 - Condition: Esophageal Cancer
Interventions: Radiation: Protracted Course Radiotherapy; Radiation: Short Course Radiotherapy
Sponsors: International Atomic Energy Agency; International Atomic Energy Agency
Completed - verified October 2011 - Conditions: Head and Neck Cancer; Xerostomia
Interventions: Drug: pilocarpine hydrochloride; Procedure: acupuncture-like transcutaneous electrical nerve stimulation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified December 2011 - Condition: Metastatic Renal Cell Cancer
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
No longer available - verified August 2011 - Conditions: Breast Cancer; Endometrial Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: metformin hydrochloride; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); London Regional Cancer Program at London Health Sciences Centre
Completed - verified August 2010 - Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBW 2992; Drug: placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Completed - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Head and Neck Cancer
Intervention: Other: PET/CT
Sponsors: University of Calgary; University of Calgary; Tom Baker Cancer Centre
Completed - verified April 2008 - Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified April 2012 - Condition: Cancer
Intervention: Drug: ARRY-380, HER2 inhibitor; oral
Sponsors: Array BioPharma; Array BioPharma
Active, not recruiting - verified February 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: brivanib alaninate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Conditions: Metastatic ErbB2; Neoplasms, Breast; Breast Cancer
Interventions: Drug: lapatinib; Drug: Digoxin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified August 2011 - Conditions: Nervous System Neoplasms; Brain Diseases; Central Nervous System Diseases; Neoplasm Metastasis; Brain Neoplasms
Interventions: Drug: ABT-888; Radiation: Whole Brain Radiation Therapy
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Condition: Solid Tumors
Interventions: Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin; Drug: MK1775; Drug: MK1775; Drug: MK1775; Drug: gemcitabine; Drug: cisplatin; Drug: carboplatin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Head and Neck Neoplasm; Prostatic Neoplasm; Pancreatic Neoplasm
Interventions: Drug: PF00562271; Drug: PF00562271; Drug: PF00562271; Drug: PF00562271
Sponsors: Pfizer; Pfizer
Completed - verified March 2012 - Condition: Extensive Stage Small Cel Lung Cancer
Intervention: Radiation: thoracic radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified April 2012 - Condition: Lung Cancer
Intervention: Other: CT scan of the chest under deep inspiration breath hold
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified August 2011 - Condition: Prostatic Neoplasms
Interventions: Drug: placebo plus prednisone/prednisolone; Drug: abiraterone acetate plus prednisone/prednisolone
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Active, not recruiting - verified August 2011 - Conditions: Advanced Non-small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Active, not recruiting - verified October 2011 - Conditions: Renal Cell Carcinoma; Kidney Cancer; Urogenital Cancer
Interventions: Drug: Bevacizumab + Temsirolimus; Drug: Bevacizumab + Interferon-Alfa
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Docetaxel; Drug: Trastuzumab; Drug: Carboplatin; Drug: Bevacizumab; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Cancer International Research Group; Hoffmann-La Roche; Genentech
Active, not recruiting - verified December 2011 - Conditions: Breast Cancer; Breast Tumors; Metastatic Cancer
Interventions: Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant
Sponsors: Amgen; Amgen
Completed - verified January 2012 - Condition: Prostate Cancer
Intervention:
Sponsors: CMX Research; CMX Research; AstraZeneca
Active, not recruiting - verified May 2011 - Condition: Urinary Bladder Neoplasms
Interventions: Drug: larotaxel (XRP9881); Drug: gemcitabine; Drug: cisplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified September 2011 - Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Biological: aflibercept
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Hematologic Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified October 2011 - Conditions: Melanoma; Lung Cancer; Renal Cell Carcinoma; Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics
Completed - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified November 2009 - Conditions: Radiotherapy Induced Mucositis; Head and Neck Cancer
Interventions: Dietary Supplement: manuka honey; Dietary Supplement: placebo gel
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Completed - verified November 2011 - Condition: Colorectal Neoplasms
Interventions: Drug: Bevacizumab (avastin); Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug: AG-013736 (axitinib); Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]); Drug: AG-013736 (axitinib); Drug: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]); Drug: Bevacizumab (avastin); Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
Sponsors: Pfizer; Pfizer
Completed - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsors: AstraZeneca; AstraZeneca
Completed - verified July 2011 - Conditions: Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: cixutumumab; Genetic: protein expression analysis; Genetic: western blotting; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Conditions: Ovarian Neoplasms; Ovarian Cancer
Interventions: Drug: AZD0530; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: AstraZeneca; AstraZeneca
Completed - verified February 2012 - Conditions: Ovarian Cancer; Endometrial Cancer
Intervention: Drug: MKC-1
Sponsors: EntreMed; EntreMed
Completed - verified January 2012 - Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified June 2011 - Condition: Nasopharyngeal Cancer
Interventions: Drug: Gemcitabine; Drug: Carboplatin/Cisplatin; Drug: erlotinib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Hoffmann-La Roche
Completed - verified October 2011 - Conditions: Solid Tumors; Breast Cancer; Cowden Syndrome
Intervention: Drug: BGT226
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012 - Condition: Ovarian Cancer
Interventions: Drug: placebo; Drug: alendronate/cholecalciferol
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Completed - verified June 2011 - Conditions: Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-751,871 (Figitumumab); Drug: Carboplatin; Drug: Paclitaxel; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Pfizer; Pfizer
Terminated - verified April 2012 - Conditions: Urothelial Cancer; Bladder Cancer; Adult
Interventions: Drug: SU011248; Drug: Placebo
Sponsors: Alberta Health Services; Alberta Health Services; Pfizer
Active, not recruiting - verified September 2011 - Condition: Breast Cancer
Intervention:
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency
Completed - verified June 2011 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: rituximab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Pancreatic Cancer
Interventions: Drug: MORAb-009; Drug: Placebo; Drug: Gemcitabine
Sponsors: Morphotek; Morphotek
Completed - verified February 2012 - Condition: Pancreatic Neoplasm
Interventions: Drug: placebo; Drug: Aflibercept (AVE0005)
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Terminated - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012 - Conditions: Lung Cancer; Tobacco Use Disorder
Interventions: Drug: defined green tea catechin extract; Other: placebo
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; National Cancer Institute (NCI); University of Cincinnati
Completed - verified March 2012 - Condition: Breast Cancer
Intervention: Drug: panobinostat, trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012 - Condition: Multiple Myeloma
Intervention: Drug: Bortezomib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Princess Margaret Hospital, Canada; Ortho Biotech, Inc.
Recruiting - verified October 2011 - Conditions: Lung Cancer; Precancerous Condition
Interventions: Drug: budesonide/formoterol fumarate dihydrate inhalation aerosol; Genetic: DNA methylation analysis; Genetic: comparative genomic hybridization; Genetic: microarray analysis; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; Astra Zeneca Canada
Completed - verified March 2012 - Conditions: Cancer; Liver Cancer; Primary Liver Cancer; Hepatocellular Carcinoma; Hepatoma
Interventions: Drug: PI-88; Drug: placebo
Sponsors: Progen Pharmaceuticals; Progen Pharmaceuticals
Terminated - verified June 2011 - Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: melphalan; Drug: thiotepa
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Irinotecan
Sponsors: Amgen; Amgen
Completed - verified July 2011 - Condition: Prostate Cancer
Interventions: Drug: ABR-215050, tasquinimod; Drug: Placebo
Sponsors: Active Biotech AB; Active Biotech AB
Active, not recruiting - verified December 2011 - Conditions: Breast Cancer; Prostate Cancer; Bone Neoplasms
Interventions: Drug: AZD0530; Drug: Zoledronic Acid
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Alimta or Taxotere
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified February 2012 - Condition: Pancreatic Cancer
Intervention: Drug: CP-675,206 and gemcitabine
Sponsors: Pfizer; Pfizer
Completed - verified August 2011 - Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib; Drug: Pazopanib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: ZD4054; Other: Best supportive care
Sponsors: AstraZeneca; AstraZeneca
Completed - verified March 2012 - Condition: Prostate Cancer
Intervention: Drug: Dutasteride
Sponsors: Canadian Urology Research Consortium; Canadian Urology Research Consortium; GlaxoSmithKline
Active, not recruiting - verified December 2011 - Conditions: Prostate Cancer; Hormone Refractory
Intervention: Drug: Sunitinib (SU011248)
Sponsors: Alberta Health Services; Alberta Health Services; Pfizer
Active, not recruiting - verified September 2011 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: pertuzumab; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; National Cancer Institute (NCI); Massachusetts General Hospital; Genentech
Active, not recruiting - verified February 2012 - Condition: Small Cell Lung Cancer
Interventions: Drug: Amrubicin; Drug: Topotecan
Sponsors: Celgene Corporation; Celgene Corporation
Completed - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: Herceptin; Drug: docetaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Conditions: Cervical Cancer; Papillomavirus Infection
Intervention: Biological: GSK Bio's HPV vaccine 580299 (Cervarix TM)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011 - Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Non-Small Cell Lung Carcinoma
Interventions: Drug: ABI-007; Drug: Taxol
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: irinotecan hydrochloride; Drug: olaparib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Recruiting - verified February 2012 - Condition: Carcinoma, Small Cell
Intervention: Drug: Pomalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Completed - verified May 2011 - Conditions: Lung Cancer; Radiation Toxicity
Interventions: Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Active, not recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard adjuvant chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified March 2012 - Condition: Multiple Myeloma
Intervention: Drug: LBH589
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed Phase 1; Drug: Cisplatin Phase 1; Procedure: Radiation Therapy; Drug: Pemetrexed Phase 2; Drug: Cisplatin Phase 2
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Active, not recruiting - verified August 2011 - Conditions: Palliative Care; Pain; Cancer
Interventions: Drug: Sativex Low Dose; Drug: Sativex Medium Dose; Drug: Sativex High Dose
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Quintiles
Completed - verified June 2011 - Condition: Multiple Myeloma
Intervention: Drug: carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Active, not recruiting - verified July 2011 - Condition: Breast Cancer
Intervention: Procedure: Blood Test
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified January 2012 - Condition: Squamous Cell Cancer
Intervention: Other: PET-CT
Sponsors: Alberta Health Services; Alberta Health Services; Calgary Health Region
Completed - verified August 2011 - Conditions: Gastro Esophageal(GE)Junction Cancer; Neoplasms, Gastrointestinal Tract; Gastric Cancer
Intervention: Drug: Lapatinib and Capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified November 2011 - Condition: Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: ABT-869
Sponsors: Abbott; Abbott; Genentech
Active, not recruiting - verified March 2012 - Conditions: Ovarian Cancer; Peritoneal Neoplasms
Intervention: Drug: Volociximab
Sponsors: Facet Biotech; Facet Biotech; Biogen Idec
Terminated - verified March 2012 - Conditions: Prostatic Neoplasms; Neoplasm Metastasis
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified April 2012 - Condition: Melanoma (Skin)
Interventions: Biological: recombinant human interleukin-21; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Condition: Cancer of the Cervix
Interventions: Drug: Sorafenib; Drug: Cisplatin; Procedure: Radiation
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Bayer
Active, not recruiting - verified October 2011 - Condition: Breast Cancer
Intervention: Procedure: Helical tomotherapy IMRT
Sponsors: Ottawa Hospital Research Institute; Ottawa Hospital Research Institute
Active, not recruiting - verified July 2007 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: HDAC inhibitor SB939; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: immunologic technique; Other: laboratory biomarker analysis; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified June 2011 - Condition: Prostate Cancer
Interventions: Procedure: conventional surgery; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: external beam radiation therapy; Procedure: PSA tests; Procedure: Biopsies; Procedure: Rectal exam
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group; Radiation Therapy Oncology Group; Breast International Group
Terminated - verified August 2011 - Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Mount Sinai Hospital, Canada; Hamilton Health Sciences Corporation
Recruiting - verified November 2008 - Condition: Neuroblastoma
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified July 2011 - Conditions: Neoplasms, Breast; Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline; North Central Cancer Treatment Group; National Cancer Institute (NCI); Breast International Group; NCIC Clinical Trials Group
Active, not recruiting - verified May 2012 - Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Cervix Cancer
Interventions: Procedure: Cervical tissue biopsy analysis: Comet assay; Procedure: Biopsy: Measurement of histone gamma H2AX phosphorylation; Procedure: Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha; Procedure: Measurement of vascular perfusion: contrast enhanced MRI
Sponsors: British Columbia Cancer Agency; British Columbia Cancer Agency; Canadian Institutes of Health Research (CIHR)
Terminated - verified February 2012 - Conditions: Ovarian Cancer; Sexual Function
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Completed - verified November 2011 - Condition: Invasive Breast Cancer
Interventions: Drug: doxorubicin; Drug: cyclophosphamide; Drug: paclitaxel; Drug: trastuzumab; Drug: lapatinib
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); GlaxoSmithKline
Active, not recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Xeloda
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsors: OncoGenex Technologies; OncoGenex Technologies
Active, not recruiting - verified December 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Procedure: quality-of-life assessment; Radiation: Radiation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC; Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified March 2012 - Conditions: Tumor Antigen-positive Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: Bevacizumab; Drug: Irinotecan; Drug: Capecitabine
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Hoffmann-La Roche
Completed - verified March 2012 - Condition: Prostate Cancer
Intervention: Drug: Ara-C (Cytarabine)
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Terminated - verified October 2011 - Condition: Breast Cancer
Interventions: Drug: trastuzumab [Herceptin]; Drug: Taxane (docetaxel or paclitaxel)
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Conditions: Bile Duct Neoplasms; Gallbladder Cancer
Intervention: Biological: Trastuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed - verified December 2011 - Condition: Breast Cancer
Interventions: Other: Interview; Procedure: Blood and Tissue Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012 - Conditions: Neoplasms, Prostate; Prostate Cancer
Interventions: Drug: dutasteride; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Renal Cell Carcinoma
Interventions: Drug: Sorafenib; Drug: temsirolimus (Torisel)
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: AG-013736; Drug: Gemcitabine; Drug: Gemcitabine; Drug: placebo
Sponsors: Pfizer; Pfizer
Completed - verified December 2011 - Conditions: Esophageal Cancer; Precancerous Condition
Interventions: Drug: acetylsalicylic acid; Drug: esomeprazole magnesium; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Completed - verified June 2010 - Conditions: Psychosocial; Cervical Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Active, not recruiting - verified March 2012 - Condition: Myelogenous Leukemia, Chronic
Interventions: Drug: nilotinib; Drug: imatinib
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Colonic Neoplasms
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified April 2012 - Condition: Lung Cancer
Interventions: Drug: Carboplatin; Drug: irinotecan hydrochloride
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Completed - verified June 2011 - Condition: Non Small Cell Lung Cancer
Intervention: Drug: Erlotinib
Sponsors: University Health Network, Toronto; University Health Network, Toronto; Hoffmann-La Roche
Recruiting - verified December 2011 - Condition: Cervical Cancer Screening
Interventions: Procedure: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive; Procedure: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR)
Recruiting - verified March 2012 - Condition: Solid Tumors
Intervention: Drug: gimatecan
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Docetaxel; Drug: Trastuzumab; Drug: Bevacizumab
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Genentech; International Drug Development Institute (IDDI)
Active, not recruiting - verified September 2011 - Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: erlotinib; Drug: sunitinib; Drug: erlotinib; Drug: placebo
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Intervention: Drug: ABI-007
Sponsors: Celgene Corporation; Celgene Corporation
Active, not recruiting - verified February 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: RAD001; Drug: erlotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Conditions: Tumor Antigen-positive Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Biological: Immunotherapeutic GSK1572932A; Drug: Cisplatin (CDDP); Drug: Vinorelbine; Procedure: Radiotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified October 2011 - Condition: Metastatic Colorectal Cancer
Interventions: Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: sunitinib; Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: placebo
Sponsors: Pfizer; Pfizer
Completed - verified June 2011 - Condition: Pancreatic Cancer
Interventions: Drug: gemcitabine; Drug: oxaliplatin; Procedure: radiation therapy
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; Sanofi-Aventis; Johns Hopkins University; Princess Margaret Hospital, Canada; Ohio State University
Active, not recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified February 2012 - Condition: Locally Advanced Breast Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012 - Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Platinum-based chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified December 2011 - Conditions: Carcinoid Tumor; Acromegaly
Intervention: Drug: Pasireotide
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified March 2012 - Conditions: Small Cell Lung Carcinoma; Small Cell Lung Cancer
Intervention: Drug: ABT-263
Sponsors: Abbott; Abbott; Genentech
Completed - verified December 2011 - Conditions: Non-Hodgkins Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: Aurora kinase inhibitor AT9283
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Conditions: Advanced Breast Cancer; Advanced Malignant Solid Tumors; Breast Neoplasms
Interventions: Drug: Combination of HKI-272 (neratinib) and paclitaxel; Drug: Combination of HKI-272 and paclitaxel; Drug: Combination of HKI-272 (neratinib) and paclitaxel; Drug: Combination of HKI-272 (neratinib) and paclitaxel
Sponsors: Puma Biotechnology, Inc.; Puma Biotechnology, Inc.
Active, not recruiting - verified May 2012 - Condition: Neoplasms
Intervention: Drug: SU011248
Sponsors: Pfizer; Pfizer
Completed - verified December 2011 - Condition: Prostate Cancer
Intervention: Drug: Goserelin Acetate
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); AstraZeneca
Active, not recruiting - verified March 2011 - Conditions: Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Myelodysplastic Syndromes; Secondary Myelofibrosis
Interventions: Biological: filgrastim; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: National Cancer Institute (NCI); The Canadian Blood and Marrow Transplant Group; National Cancer Institute (NCI)
Recruiting - verified July 2009 - Condition: Malnourished Children With Cancer
Interventions: Drug: Megstrol Acetate; Other: Placebo
Sponsors: University of British Columbia; University of British Columbia; University of Alberta
Recruiting - verified October 2011 - Condition: Breast Neoplasms
Interventions: Drug: Sunitinib + Capecitabine; Drug: Capecitabine
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Breast Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre; ART Advanced Research Technologies Inc.
Recruiting - verified April 2012 - Condition: Locally Advanced Breast Cancer
Intervention:
Sponsors: Sunnybrook Health Sciences Centre; Sunnybrook Health Sciences Centre
Recruiting - verified April 2012 - Conditions: Neoplasms, Uterine Cervix; Metastatic Cervical Cancer
Interventions: Drug: pazopanib (GW786034); Drug: lapatinib (GW572016)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011 - Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Prostate Cancer
Interventions: Drug: risedronate; Drug: risedronate; Drug: Control
Sponsors: CMX Research; CMX Research; Sanofi-Aventis
Completed - verified February 2012 - Condition: Solid Tumors
Intervention: Drug: gimatecan
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Condition: Pancreatic Neoplasms
Interventions: Drug: larotaxel (XRP9881); Drug: 5-Fluorouracil
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Completed - verified August 2011 - Condition: Pancreatic Cancer
Intervention: Procedure: Positron-Emission Tomography (PET) 18F-FLT
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Biological: Stimuvax; Biological: Placebo
Sponsors: EMD Serono; EMD Serono; Merck KGaA
Active, not recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: AC regimen; Drug: capecitabine; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified July 2010 - Condition: Thyroid Cancer
Intervention: Drug: ZD6474 (Vandetanib)
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified April 2011 - Condition: Metastatic Renal Cell Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Conditions: Endometrial Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified January 2012 - Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: fluorouracil; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified June 2009 - Condition: Bladder Neoplasms
Intervention: Drug: Mycobacterial cell wall-DNA complex
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Active, not recruiting - verified July 2011 - Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: ZD6474 (vandetanib); Other: Best Supportive Care
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified April 2011 - Condition: Breast Neoplasms
Interventions: Drug: Sunitinib malate; Drug: Taxotere
Sponsors: Pfizer; Pfizer
Completed - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: HYCAMTIN, oral capsules; Radiation: Radiation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Cervical Cancer
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011 - Condition: Malignant Mesothelioma
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified January 2012 - Condition: Thyroid Neoplasms
Intervention: Drug: AG-013736
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified May 2012 - Conditions: Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: CDKI AT7519; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Drug: sunitinib malate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: everolimus; Drug: temozolomide; Genetic: microarray analysis; Other: immunohistochemistry staining method
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: E7389; Drug: Physician's Choice
Sponsors: Eisai Inc.; Eisai Inc.; Eisai Limited
Completed - verified March 2012 - Condition: Breast Neoplasms
Interventions: Behavioral: Mindfulness Meditation-Based Stress Reduction; Behavioral: Supportive-Expressive Group Therapy
Sponsors: Alberta Health Services; Canadian Breast Cancer Research Alliance; British Columbia Cancer Agency
Active, not recruiting - verified August 2011 - Conditions: Neoplasms, Head and Neck; Cancer
Interventions: Drug: Lapatinib oral tablets; Drug: radiotherapy; Drug: cisplatin chemotherapy
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Colorectal Cancer
Interventions: Drug: Cediranib; Drug: Bevacizumab; Drug: 5-fluorouracil ( in FOLFOX); Drug: Leucovorin (in FOLFOX); Drug: Oxaliplatin (in FOLFOX)
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified June 2011 - Condition: Pancreatic Cancer
Intervention: Drug: eribulin mesylate
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified July 2009 - Conditions: Head and Neck Cancer; Squamous Cell Cancer
Interventions: Drug: Zalutumumab; Other: Best Supportive Care
Sponsors: Genmab; Genmab
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Other: Placebo
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Novartis
Active, not recruiting - verified September 2011 - Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012 - Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Conditions: Bone Neoplasms; Pain, Intractable; Cancer
Interventions: Drug: Pregabalin; Drug: Placebo
Sponsors: Pfizer; Pfizer
Terminated - verified August 2011 - Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified July 2011 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: Tarceva; Drug: Placebo
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; Astellas Pharma Global Development, Inc.
Active, not recruiting - verified March 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Breast Neoplasms
Interventions: Drug: Capecitabine; Drug: Sunitinib malate
Sponsors: Pfizer; Pfizer
Terminated - verified July 2011 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AEG35156; Drug: docetaxel; Genetic: protein expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: flow cytometry; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Condition: Lung Cancer
Intervention: Drug: Motexafin Gadolinium
Sponsors: Pharmacyclics; Pharmacyclics
Completed - verified August 2010 - Condition: Head and Neck Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Condition: Head and Neck Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Condition: Breast Neoplasms
Interventions: Drug: CP-751,871; Drug: exemestane; Drug: exemestane
Sponsors: Pfizer; Pfizer
Terminated - verified May 2012 - Condition: Lung Cancer
Interventions: Drug: satraplatin and erlotinib; Drug: erlotinib
Sponsors: Agennix; Agennix
Completed - verified May 2012 - Condition: Non-small-cell Lung Cancer
Interventions: Procedure: External radiotherapy; Biological: nimotuzumab
Sponsors: YM BioSciences; YM BioSciences; CIMYM BioSciences
Terminated - verified June 2011 - Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified August 2009 - Conditions: Lung Cancer; Precancerous Condition; Tobacco Use Disorder
Interventions: Drug: sulindac; Other: placebo
Sponsors: National Cancer Institute (NCI); Mayo Clinic; National Cancer Institute (NCI)
Completed - verified August 2009 - Conditions: Neoplasms, Prostate; Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Matching placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Condition: Colorectal Neoplasms
Intervention: Drug: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Sponsors: Celator Pharmaceuticals; Celator Pharmaceuticals
Completed - verified May 2012 - Conditions: Islet Cell Carcinoma; Neuroendocrine Carcinoma; Neuroendocrine Tumor; Pancreatic Neoplasms
Intervention: Drug: Everolimus 10 mg
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified March 2012 - Conditions: Brain and Central Nervous System Tumors; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ispinesib; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: immunohistochemistry staining method; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: AEG35156; Drug: docetaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Conditions: Breast Cancer; Osteoporosis
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: cholecalciferol; Drug: alendronate sodium; Drug: calcium gluconate; Drug: risedronate sodium; Other: laboratory biomarker analysis; Procedure: dual x-ray absorptometry
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Southwest Oncology Group
Completed - verified January 2012 - Condition: Metastatic Breast Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified December 2011 - Condition: Bladder Cancer
Interventions: Biological: BCG vaccine; Drug: gefitinib; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Conditions: Brain and Central Nervous System Tumors; Neurofibromatosis Type 1
Interventions: Drug: carboplatin; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Conditions: Lung Neoplasms; Lung Cancer
Intervention: Procedure: Fractionated Stereotactic Radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified January 2012 - Condition: Lung Cancer
Intervention: Radiation: 3-dimensional conformal radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Paclitaxel and Carboplatin; Drug: NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin
Sponsors: Novelos Therapeutics; Novelos Therapeutics
Completed - verified March 2010 - Condition: Neoplasms, Breast
Interventions: Drug: pazopanib (GW786034) 400 mg; Drug: lapatinib (GW572016) 1500 mg; Drug: lapatinib (GW572016) 1000 mg; Drug: pazopanib (GW786034) 800 mg
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Conditions: Childhood Malignant Fibrous Histiocytoma of Bone; Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide; Other: clinical observation; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: E7389; Drug: Capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Completed - verified April 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: Docetaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Active, not recruiting - verified April 2012 - Condition: Retinoblastoma
Interventions: Drug: carboplatin; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone; Drug: OGX-011
Sponsors: OncoGenex Technologies; OncoGenex Technologies
Completed - verified July 2011 - Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012 - Condition: Anemia
Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: methoxy polyethylene glycol-epoetin beta [Mircera]; Drug: Darbepoetin alfa
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011 - Conditions: Neoplasms; Cancer of the Ovary
Interventions: Drug: AVE0005 (VEGF Trap); Drug: AVE0005 (VEGF Trap)
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified August 2011 - Conditions: Ovarian Neoplasms; Ascites
Interventions: Drug: aflibercept (AVE0005 / VEGF Trap); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Completed - verified July 2011 - Condition: Ovarian Neoplasms
Intervention: Drug: Sagopilone (ZK 219477) + carboplatin
Sponsors: Bayer; Bayer
Completed - verified November 2011 - Condition: Gastrointestinal Stromal Tumor
Interventions: Biological: bevacizumab; Drug: imatinib mesylate
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group
Active, not recruiting - verified September 2009 - Conditions: Tumors; Non Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
Sponsors: MethylGene Inc.; MethylGene Inc.
Completed - verified May 2009 - Conditions: Thrombosis; Cancer; Pulmonary Embolism
Interventions: Drug: Apixaban; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ontario Clinical Oncology Group (OCOG)
Completed - verified February 2012 - Conditions: Renal Cell Carcinoma; Neuroendocrine Tumours
Intervention: Drug: 18F-FAZA PET Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified March 2012 - Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Conditions: Leukemia; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: dasatinib
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Conditions: Advanced Breast Cancer; Metastatic Breast Cancer
Intervention: Drug: Fulvestrant
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified April 2012 - Condition: Breast Neoplasm
Interventions: Drug: Sagopilone (ZK 219477); Drug: Sagopilone (ZK 219477)
Sponsors: Bayer; Bayer
Completed - verified November 2011 - Condition: Prostatic Neoplasms
Interventions: Drug: CP-751,871; Drug: docetaxel; Drug: prednisone; Drug: docetaxel; Drug: prednisone
Sponsors: Pfizer; Pfizer
Completed - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: docetaxel, doxorubicin, cyclophosphamide; Drug: Docetaxel,doxorubicin, cyclophosphamide
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Cancer International Research Group
Active, not recruiting - verified August 2011 - Condition: Prostate Cancer
Intervention: Device: Magnetic Resonance Spectroscopy (3Tesla)
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Condition: Lung Cancer
Interventions: Procedure: computed tomography; Procedure: positron emission tomography
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2007 - Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified October 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Completed - verified May 2009 - Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011 - Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel; Drug: Carboplatin plus Paclitaxel
Sponsors: Bayer; Bayer
Terminated - verified November 2011 - Condition: Rectal Cancer
Intervention: Procedure: surgery
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Active, not recruiting - verified March 2010 - Condition: Prophylaxis for HPV Infections and Associated Cervical Neoplasia
Interventions: Biological: Cervarix; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012 - Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsors: EDAP TMS S.A.; EDAP TMS S.A.
Active, not recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: Degarelix; Drug: Degarelix; Drug: Leuprolide 7.5 mg
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified December 2011 - Condition: Breast Cancer
Interventions: Radiation: 3D-CRT APBI; Radiation: WBI
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Canadian Breast Cancer Research Alliance
Active, not recruiting - verified July 2011 - Condition: Anaplastic Thyroid Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified July 2011 - Conditions: Lung Cancer, Small Cell; Small Cell Lung Cancer
Intervention: Drug: topotecan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified May 2012 - Condition: Renal Cell Carcinoma
Intervention: Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Active, not recruiting - verified January 2012 - Conditions: Prostatic Neoplasms; Neoplasm Metastasis; Palliative Care
Intervention: Behavioral: Exercise training
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Conditions: Neoplasms, Endometrial; Endometrial Cancer
Intervention: Drug: topotecan
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified November 2011 - Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified September 2009 - Condition: Pancreatic Cancer
Interventions: Drug: AZD0530; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Conditions: Colorectal Cancer; Liver Metastases
Intervention: Procedure: PET diagnostic imaging
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Active, not recruiting - verified October 2011 - Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: sunitinib; Drug: erlotinib; Drug: placebo
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
Interventions: Drug: EPO906 (Patupilone); Drug: doxorubicin
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified May 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: docetaxel; Drug: prednisone
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: NSCLC
Intervention: Drug: Gefitinib
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified February 2012 - Condition: Breast Cancer
Intervention: Drug: E7389
Sponsors: Eisai Inc.; Eisai Inc.; Eisai Limited
Completed - verified April 2012 - Condition: Breast Cancer
Intervention: Behavioral: Physical exercise
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified April 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cediranib maleate; Drug: paclitaxel; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified August 2011 - Condition: Breast Cancer
Intervention: Drug: Letrozole, anastrozole
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Breast Neoplasms
Interventions: Drug: SU011248; Drug: Chemotherapy
Sponsors: Pfizer; Pfizer
Completed - verified September 2011 - Condition: Breast Neoplasms
Intervention: Drug: SU011248/Trastuzumab
Sponsors: Pfizer; Pfizer
Completed - verified July 2011 - Condition: Breast Cancer
Interventions: Drug: letrozole; Other: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Bladder Cancer
Interventions: Biological: trastuzumab; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Neoplasms
Interventions: Drug: Gefitinib; Drug: Tamoxifen
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified February 2012 - Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: isotretinoin; Drug: vorinostat
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; British Medical Research Council; Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified February 2012 - Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine; Drug: AG-013736 plus gemcitabine
Sponsors: Pfizer; Pfizer
Completed - verified January 2012 - Conditions: Cancer; Spinal Fractures
Interventions: Device: Balloon Kyphoplasty; Other: Non Surgical Management
Sponsors: Medtronic Spine LLC; Medtronic Spine LLC
Completed - verified May 2010 - Condition: Breast Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Completed - verified August 2011 - Condition: Non-small Cell Lung Cancer
Intervention:
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified November 2011 - Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: strontium-89; Drug: cisplatin
Sponsors: Alberta Health Services; Alberta Health Services; Prostate cancer research foundation; Amersham Health
Completed - verified August 2008 - Conditions: Lung Cancer; Mesothelioma
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified January 2012 - Condition: Lung Cancer
Intervention:
Sponsors: University Health Network, Toronto; University Health Network, Toronto
Recruiting - verified February 2012 - Condition: Head and Neck Cancer
Interventions: Procedure: radiation treatment and surgery; Procedure: radiation alone
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified October 2011 - Conditions: Multiple Sclerosis; Optic Neuritis; Transverse Myelitis; Acute Brainstem/Cerebellar Syndrome
Intervention: Drug: interferon beta 1a 30 ug IM once weekly
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; Biogen Idec
Completed - verified June 2011 - Condition: Breast Cancer
Intervention: Procedure: Scar massage.
Sponsors: University of British Columbia; University of British Columbia
Active, not recruiting - verified September 2011 - Condition: Prostate Cancer
Intervention: Drug: luteinizing hormone-releasing hormone (LHRH) short acting or long acting
Sponsors: University of British Columbia; University of British Columbia
Recruiting - verified February 2012 - Condition: - Breast Cancer
Intervention: Procedure: Aloe barbadensis topical application in a moisturizing cream vehicle.
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified December 2011 - Condition: Non-small Cell Lung Cancer
Intervention: Drug: custirsen sodium
Sponsors: OncoGenex Technologies; OncoGenex Technologies
Completed - verified February 2012 - Condition: Non-small-cell Lung Carcinoma
Intervention: Procedure: PET Imaging
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Active, not recruiting - verified March 2012 - Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)Condition: Non-Small-Cell Lung Carcinoma
Intervention: Procedure: PET Diagnostic Imaging
Sponsors: Ontario Clinical Oncology Group (OCOG); Ontario Clinical Oncology Group (OCOG); Ontario Ministry of Health and Long Term Care
Completed - verified November 2011 - Condition: Prostate Cancer
Intervention: Biological: OGX-011
Sponsors: University of British Columbia; University of British Columbia; Department of Defense
Recruiting - verified April 2012 - Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With OsteosarcomaCondition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011 - Conditions: Lung Cancer; Colorectal Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified April 2012 - Condition: Colon Cancer
Intervention: Drug: 5FU/LV
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified December 2011 - Condition: Carcinoma, Renal Cell
Intervention: Drug: Sutent
Sponsors: Pfizer; Pfizer
Approved for marketing - verified March 2012 - Condition: Prostate Cancer
Intervention: Procedure: Hypofractionated radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified October 2011 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: erlotinib hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified October 2007 - Condition: Colon Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Recruiting - verified April 2012 - Condition: Prostate Cancer
Intervention: Procedure: Tomotherapy
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified April 2012 - Condition: Cervix Cancer
Intervention: Procedure: CT and MR fusion
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified December 2011 - Condition: Prostatic Neoplasm
Intervention: Procedure: Magnetic Resonance Spectroscopy Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Condition: Prostate Cancer
Intervention: Procedure: radiotherapy
Sponsors: Alberta Health Services; Alberta Health Services; Calgary Health Region
Completed - verified January 2012 - Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant RecipientsConditions: Skin Neoplasms; Kidney Transplantation
Interventions: Drug: sirolimus; Drug: cyclosporine or tacrolimus
Sponsors: Wyeth is now a wholly owned subsidiary of Pfizer; Wyeth is now a wholly owned subsidiary of Pfizer
Completed - verified April 2012 - Conditions: Human Papillomavirus (HPV) Infection; Cervical Neoplasia
Interventions: Biological: Cervarix™; Biological: Havrix™-based investigational formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012 - Conditions: Prostate Cancer; Osteoporosis
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified December 2011 - Condition: Cervix Cancer
Intervention: Procedure: Megavoltage CT scan
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified April 2012 - Conditions: Brain Neoplasms; Lung Neoplasms; Thyroid Neoplasms; Colorectal Neoplasms; Lymphoma
Intervention: Procedure: Positron Emission Tomography (PET) scan
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Conditions: Sarcoma; Multiple Myeloma; Testicular Neoplasms; Ovarian Neoplasms; Kidney Neoplasms
Intervention: Procedure: Positron Emission Tomography
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Condition: Lung Neoplasms
Intervention: Procedure: Positron Emission Tomography (PET) scan Imaging
Sponsors: Alberta Health Services; Alberta Health Services
Completed - verified March 2012 - Conditions: Breast Cancer; Glioma; Prostate Cancer; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell-Lung; Head and Neck Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified March 2012 - Conditions: Rectal Cancer; Neoplasm Metastasis
Interventions: Drug: Capecitabine; Procedure: Pelvic radiation
Sponsors: Alberta Health Services; Alberta Health Services
Active, not recruiting - verified August 2011 - Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified December 2011 - Condition: Prostate Cancer
Intervention:
Sponsors: Alberta Health Services; Alberta Health Services
Terminated - verified April 2012 - Condition: Cervix Cancer
Interventions: Radiation: Radiotherapy; Radiation: Radiotherapy; Radiation: Radiotherapy/Cisplatin; Radiation: Radiotherapy/Cisplatin
Sponsors: International Atomic Energy Agency; International Atomic Energy Agency
Completed - verified October 2011 - Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Completed - verified December 2011 - Condition: Gastric Cancer
Interventions: Drug: S-1/Cisplatin; Drug: 5-FU/cisplatin
Sponsors: Taiho Pharma USA, Inc.; Taiho Pharma USA, Inc.; Quintiles
Completed - verified March 2012 - Condition: Ovarian Cancer
Interventions: Drug: Trabectedin; Drug: DOXIL; Drug: DOXIL
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Completed - verified April 2012 - Conditions: Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); Hypereosinophilic Syndrome; Systemic Mastocytosis
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Active, not recruiting - verified April 2012 - Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cyclosporine; Drug: etoposide; Drug: vincristine sulfate; Procedure: cryosurgery; Procedure: laser therapy; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); The Hospital for Sick Children
Recruiting - verified April 2009 - Conditions: Brain and Central Nervous System Tumors; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: valproic acid
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Breast Neoplasm
Interventions: Drug: RAD001, Letrozole 2.5mg; Drug: Letrozole 2.5mg
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified November 2011 - Conditions: Preneoplastic Conditions; Prostatic Intraepithelial Neoplasia
Interventions: Drug: Toremifene 20 mg; Drug: Placebo
Sponsors: GTx; GTx
Completed - verified October 2010 - Condition: Lung Cancer
Interventions: Procedure: conventional surgery; Procedure: therapeutic thoracoscopy; Radiation: brachytherapy; Radiation: iodine I 125
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Active, not recruiting - verified January 2010 - Conditions: Adenocarcinoma; Neoplasms
Intervention: Drug: Torisel
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer
Completed - verified January 2012 - Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Bortezomib (VELCADE); Drug: Bortezomib (VELCADE); Drug: Doxorubicin hydrochloride (DOXIL/CAELYX)
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Active, not recruiting - verified May 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Colorectal Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lymphoma; Melanoma (Skin); Neuroblastoma; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: irinotecan hydrochloride; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Brain and Central Nervous System Tumors
Intervention: Drug: lapatinib ditosylate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified April 2012 - Conditions: Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: amifostine trihydrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Liver Cancer
Intervention: Drug: ispinesib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011 - Conditions: Lung Cancer; Metastatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: temozolomide; Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified August 2009 - Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: cetuximab; Drug: Pemetrexed
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Completed - verified September 2011 - Condition: Melanoma (Skin)
Intervention: Drug: ispinesib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011 - Conditions: Melanoma; Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody; Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Completed - verified June 2011 - Condition: Gastrointestinal Neoplasm
Intervention: Drug: Sutent
Sponsors: Pfizer; Pfizer
Approved for marketing - verified March 2012 - Condition: Prostate Cancer
Intervention: Drug: sorafenib tosylate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011 - Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Placebo; Drug: ZD4054 (Zibotentan)
Sponsors: AstraZeneca; AstraZeneca
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified April 2011 - Condition: Renal Cell Carcinoma
Intervention: Biological: MB-002
Sponsors: Argos Therapeutics; Argos Therapeutics
Completed - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified January 2012 - Condition: Prostate Cancer
Interventions: Biological: GTI-2040; Drug: docetaxel; Drug: prednisone
Sponsors: National Cancer Institute (NCI); Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Completed - verified November 2005 - Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: cetuximab; Drug: carboplatin
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified September 2005 - Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: Temsirolimus (CCI-779) for 34 months; Drug: Letrozole for 34 months
Sponsors: Wyeth is now a wholly owned subsidiary of Pfizer; Wyeth is now a wholly owned subsidiary of Pfizer
Terminated - verified November 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012 - Conditions: Cervical Cancer; Precancerous Condition
Interventions: Procedure: Colposcopic biopsy; Procedure: Light-Scattering Spectroscopy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed - verified July 2011 - Condition: Breast Cancer
Intervention: Drug: exemestane
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; Grupo Espanol de Investigacion del Cancer de Mama; UNICANCER
Active, not recruiting - verified August 2011 - Conditions: Metastatic Cancer; Pain
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Radiation Therapy Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); Cancer Research UK; Dutch Bone Metastasis Study Group; Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2011 - Conditions: Kidney Cancer; Leukemia; Lymphoma; Neuroblastoma; Oral Complications; Sarcoma
Intervention: Dietary Supplement: Traumeel S
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Completed - verified November 2009 - Condition: Glioblastoma Multiforme
Interventions: Drug: IL13-PE38QQR; Procedure: surgery and catheter placement (2 procedures); Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer); Procedure: surgery and wafer placement (1 procedure)
Sponsors: Insys Therapeutics Inc; Insys Therapeutics Inc
Completed - verified June 2011 - Condition: Lung Cancer
Interventions: Genetic: proteomic profiling; Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Completed - verified April 2006 - Condition: Breast Neoplasms
Interventions: Drug: Placebo; Drug: Docetaxel; Drug: AG-013736 (axitinib); Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Completed - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: fulvestrant
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Active, not recruiting - verified June 2011 - Condition: Pancreatic Cancer
Interventions: Biological: cetuximab; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group
Completed - verified April 2012 - Conditions: Leukemia; Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases
Interventions: Biological: Allogeneic bone marrow transplantation; Biological: Peripheral blood stem cell transplantation
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Active, not recruiting - verified January 2012 - Condition: Neoplasms, Breast
Interventions: Drug: Lapatinib (GW572016); Drug: Letrozole
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified April 2012 - Condition: Carcinoma, Renal Cell
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Bayer; Onyx Pharmaceuticals
Completed - verified November 2011 - Condition: Endometrial Cancer
Intervention: Drug: temsirolimus
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Completed - verified September 2011 - Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); NCIC Clinical Trials Group; Eastern Cooperative Oncology Group
Active, not recruiting - verified April 2011 - Conditions: Extragonadal Germ Cell Tumor; Testicular Germ Cell Tumor
Interventions: Drug: cisplatin; Drug: ifosfamide; Drug: paclitaxel; Drug: vinblastine
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI)
Terminated - verified June 2011 - Condition: Breast Cancer
Interventions: Procedure: breast imaging study; Procedure: comparison of screening methods; Procedure: magnetic resonance imaging; Procedure: radiomammography; Procedure: ultrasound imaging
Sponsors: National Cancer Institute (NCI); American College of Radiology Imaging Network; National Cancer Institute (NCI)
Completed - verified February 2006 - Condition: Sarcoma
Interventions: Drug: trabectedin; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: AC regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified January 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Leucovorin; Drug: 5 FU; Drug: Oxaliplatin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5 FU; Drug: Avastin; Drug: Avastin
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified July 2011 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Oxaliplatin; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5 FU
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group; International Breast Cancer Study Group
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Active, not recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: docetaxel; Drug: epirubicin hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Active, not recruiting - verified May 2010 - Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Conditions: Carcinoma, Renal Cell; Kidney Neoplasms
Interventions: Drug: Interferon Alfa; Drug: CCI-779; Drug: Interferon Alfa and CCI-779
Sponsors: Pfizer; Pfizer
Completed - verified June 2011 - Conditions: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Exemestane
Sponsors: AstraZeneca; AstraZeneca
Active, not recruiting - verified March 2012 - Conditions: Non-Small-Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: Topotecan/Docetaxel combination; Drug: Docetaxel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified June 2011 - Condition: Multiple Myeloma
Intervention: Drug: bortezomib
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Completed - verified January 2012 - Conditions: Metastatic Breast Cancer; Neoplasms, Breast
Intervention: Drug: GW572016
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified April 2012 - Condition: Lung Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified October 2008 - Conditions: Leukemia; Lymphoma
Interventions: Biological: filgrastim; Biological: rituximab; Drug: carboplatin; Drug: cytarabine; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Cervical Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: paclitaxel
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified June 2011 - Conditions: Neoplasms, Prostate; Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: tamoxifen citrate; Radiation: Radiation Therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); North Central Cancer Treatment Group; Southwest Oncology Group; American College of Surgeons
Active, not recruiting - verified January 2012 - Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Completed - verified July 2011 - Conditions: Esophageal Cancer; Gastric Cancer
Interventions: Drug: cisplatin; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: leucovorin calcium; Radiation: radiation therapy
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); North Central Cancer Treatment Group; Eastern Cooperative Oncology Group
Active, not recruiting - verified April 2011 - Condition: Neuroblastoma
Intervention: Drug: fenretinide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Lung Cancer
Interventions: Drug: IRESSA (ZD1839); Other: Placebo comparator
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Completed - verified January 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide; Other: clinical observation
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Active, not recruiting - verified September 2011 - Condition: Multiple Myeloma
Intervention: Drug: bortezomib
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Completed - verified January 2012 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor
Interventions: Biological: filgrastim; Biological: graft-versus-tumor induction therapy; Drug: carboplatin; Drug: etoposide; Drug: ifosfamide; Drug: thiotepa; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Procedure: adjuvant therapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; International Breast Cancer Study Group
Active, not recruiting - verified March 2012 - Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: etoposide; Drug: irinotecan hydrochloride
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; Cancer and Leukemia Group B
Active, not recruiting - verified June 2011 - Condition: Lymphoma
Intervention: Drug: bortezomib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Completed - verified September 2011 - Condition: Lung Cancer
Interventions: Biological: monoclonal antibody 11D10 anti-idiotype vaccine; Biological: monoclonal antibody GD2 anti-idiotype vaccine; Drug: cisplatin; Drug: etoposide; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified June 2011 - Condition: Pancreatic Cancer
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774)
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; NCIC Clinical Trials Group
Completed - verified November 2011 - Condition: Carcinoma, Non-small-cell Lung
Intervention: Drug: Tarceva (erlotinib HCl, OSI-774 )
Sponsors: OSI Pharmaceuticals; OSI Pharmaceuticals; NCIC Clinical Trials Group
Completed - verified November 2011 - Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms
Intervention: Drug: epothilone b
Sponsors: Novartis; Novartis Pharmaceuticals
Completed - verified April 2012 - Conditions: Gastrointestinal Stromal Tumor; Metastatic Cancer; Neuroblastoma; Sarcoma
Intervention: Drug: imatinib mesylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified September 2004 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: Paclitaxel
Sponsors: Eastern Cooperative Oncology Group; Eastern Cooperative Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Completed - verified January 2010 - Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Sarcoma
Interventions: Biological: filgrastim; Biological: sargramostim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: tirapazamine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Pancreatic Cancer
Interventions: Drug: exatecan mesylate; Drug: gemcitabine hydrochloride
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Completed - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Standard Treatment; Drug: capecitabine
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011 - Condition: Prostate Cancer
Interventions: Procedure: conventional surgery; Radiation: brachytherapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Completed - verified October 2003 - Condition: Sarcoma
Interventions: Biological: filgrastim; Biological: trastuzumab; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Drug: releasing hormone agonist therapy; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Completed - verified January 2005 - Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: docetaxel; Drug: etoposide; Drug: gefitinib; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; NCIC Clinical Trials Group
Completed - verified June 2011 - Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011 - Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin; Drug: tirapazamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2008 - Conditions: Anemia; Cervical Cancer; Drug/Agent Toxicity by Tissue/Organ; Radiation Toxicity
Interventions: Biological: epoetin alfa; Drug: cisplatin; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Completed - verified May 2004 - Conditions: Esophageal Cancer; Gastric Cancer
Intervention: Drug: exatecan mesylate
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Completed - verified May 2012 - Condition: Breast Cancer
Interventions: Biological: epoetin alfa; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Drug: fluorouracil; Drug: paclitaxel
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; North Central Cancer Treatment Group; Southwest Oncology Group
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: capecitabine [Xeloda]; Drug: Leucovorin; Drug: 5-FU
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Completed - verified November 2011 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: aldesleukin; Biological: filgrastim; Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: fludarabine phosphate; Drug: idarubicin; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: thioguanine; Procedure: allogeneic bone marrow transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified October 2002 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); AGO Study Group; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified June 2011 - Condition: Prostate Cancer
Interventions: Radiation: brachytherapy; Radiation: iodine I 125; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified February 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: tamoxifen citrate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified May 2006 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Active, not recruiting - verified September 2011 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: rebimastat
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified August 2011 - Condition: Breast Cancer
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); Radiation Therapy Oncology Group; Southwest Oncology Group; Trans-Tasman Radiation Oncology Group (TROG); North Central Cancer Treatment Group
Active, not recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: aromatase inhibition therapy; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel; Drug: tamoxifen citrate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group; NCIC Clinical Trials Group
Active, not recruiting - verified January 2006 - Condition: Sarcoma
Intervention: Drug: alvocidib
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Breast Cancer
Interventions: Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting - verified June 2011 - Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Bladder Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: methotrexate; Drug: vinblastine; Procedure: adjuvant therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group; USC/Norris Comprehensive Cancer Center
Active, not recruiting - verified June 2011 - Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group
Completed - verified February 2004 - Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified May 2012 - Condition: Neuroblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: isotretinoin; Drug: melphalan; Drug: topotecan hydrochloride; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: bone marrow ablation with stem cell support; Procedure: conventional surgery; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: AC-T regimen; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: endocrine-modulating drug therapy; Drug: paclitaxel; Drug: tamoxifen citrate; Radiation: radiation therapy
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified January 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012 - Condition: Colorectal Cancer
Interventions: Drug: FOLFIRI regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); North Central Cancer Treatment Group; NCIC Clinical Trials Group; Southwest Oncology Group; Eastern Cooperative Oncology Group
Completed - verified December 2011 - Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: vinorelbine ditartrate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; Cancer and Leukemia Group B
Completed - verified March 2012 - Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Biological: filgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified April 2003 - Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Colorectal Cancer
Interventions: Procedure: conventional surgery; Procedure: laparoscopic surgery
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Active, not recruiting - verified October 2002 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified April 2009 - Condition: Breast Cancer
Interventions: Drug: letrozole; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); North Central Cancer Treatment Group; International Breast Cancer Study Group; Eastern Cooperative Oncology Group; Southwest Oncology Group; Cancer and Leukemia Group B; European Organization for Research and Treatment of Cancer - EORTC
Completed - verified March 2012 - Condition: Lung Cancer
Interventions: Drug: marimastat; Drug: Placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified January 2012 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: cyproterone acetate; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group
Active, not recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: octreotide acetate; Drug: tamoxifen citrate
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal WomenCondition: Breast Cancer
Interventions: Drug: Raloxifene; Drug: Tamoxifen
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Eli Lilly and Company; AstraZeneca
Active, not recruiting - verified September 2011 - Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; NCIC Clinical Trials Group; Eastern Cooperative Oncology Group; Southwest Oncology Group
Completed - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Active, not recruiting - verified September 2011 - Condition: Colorectal Cancer
Intervention: Biological: edrecolomab
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group
Completed - verified August 2011 - Condition: Prostate Cancer
Interventions: Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2011 - Condition: Prostate Cancer
Intervention: Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified February 2012 - Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide; Procedure: orchiectomy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group; Medical Research Council
Completed - verified January 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Procedure: surgical resection
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Completed - verified April 2011 - Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Endometrial Cancer
Intervention: Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified April 2012 - Condition: Metastatic Cancer
Interventions: Drug: talc; Drug: Talc
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; North Central Cancer Treatment Group
Completed - verified March 2011 - Conditions: Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: asparaginase; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: thioguanine
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: dexamethasone; Drug: melphalan; Drug: prednisone
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Neuroblastoma
Interventions: Biological: filgrastim; Biological: sargramostim; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Procedure: adjuvant therapy; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified August 2011 - Condition: Endometrial Cancer
Intervention: Drug: danazol
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified July 2004 - Condition: Lung Cancer
Interventions: Other: immunohistochemistry staining method; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Completed - verified October 2004 - Condition: Lung Cancer
Intervention: Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Active, not recruiting - verified July 2003 - Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group; Southwest Oncology Group; Children's Oncology Group
Active, not recruiting - verified June 2011 - Condition: Neuroblastoma
Interventions: Biological: filgrastim; Biological: sargramostim; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; Children's Oncology Group
Suspended - verified July 2011 - Conditions: Cardiac Toxicity; Sarcoma
Interventions: Drug: cisplatin; Drug: dexrazoxane hydrochloride; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified March 2012 - Condition: Sarcoma
Interventions: Biological: dactinomycin; Biological: filgrastim; Biological: sargramostim; Drug: cyclophosphamide; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010 - Conditions: Anemia; Breast Cancer; Chronic Myeloproliferative Disorders; Drug/Agent Toxicity by Tissue/Organ; Leukemia; Lung Cancer; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: epoetin alfa; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified November 2006 - Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: cisplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified January 2012 - Conditions: Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified December 2011 - Condition: Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: levamisole hydrochloride
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; North Central Cancer Treatment Group
Completed - verified December 2011 - Condition: Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: levamisole hydrochloride; Radiation: radiation therapy
Sponsors: Southwest Oncology Group; Southwest Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group; North Central Cancer Treatment Group; NCIC Clinical Trials Group; Cancer and Leukemia Group B
Active, not recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: Cancer and Leukemia Group B; Cancer and Leukemia Group B; National Cancer Institute (NCI); North Central Cancer Treatment Group; Eastern Cooperative Oncology Group; Southwest Oncology Group
Active, not recruiting - verified March 2011 - Condition: Breast Cancer
Interventions: Procedure: axillary lymph node dissection; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Active, not recruiting - verified September 2004 - Conditions: Endometrial Cancer; Sarcoma
Interventions: Procedure: conventional surgery; Procedure: laparoscopic surgery
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Completed - verified September 2005 - Condition: Pancreatic Cancer
Interventions: Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Completed - verified April 2003 - Condition: Esophageal Cancer
Interventions: Drug: chemotherapy; Drug: cisplatin; Drug: fluorouracil; Radiation: low-LET electron therapy; Radiation: low-LET photon therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; North Central Cancer Treatment Group
Completed - verified June 2011 - Conditions: Brain and Central Nervous System Tumors; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: temozolomide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: New York University School of Medicine; New York University School of Medicine
Withdrawn - verified June 2011 - Condition: Gestational Trophoblastic Tumor
Interventions: Biological: dactinomycin; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group
Completed - verified August 2007


